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Abstract  
                                                                                                      
Pyrazine derivatives possess numerous pharmacological effects including but not limited to 
antiviral, antibiotic, antifungal, diuretic, anticonvulsant, antidiabetic, analgesic and anti 
proliferative effect. Consequently, interest has been shown by researchers in the field of 
pyrazine-based drug synthesis and many of the synthesized derivatives succeeded to reach the 
clinical field. A promising research discipline was concerned in utilizing the antiproliferative and 
cytotoxic activity of pyrazine derivatives -that is attributed to various mechanisms one of which 
is protein kinase inhibition- in designing new anti-cancer agents.  
 
In this study a set of disubstituted pyrazine derivatives has been designed and synthesized 
through a sequential nucleophilic substitution of chlorine atoms of 2,3-dichloropyrazine with 
amines or other nucleophiles. The synthesized derivatives were purified using several 
chromatographic techniques, and characterized by (
1
H-NMR, 
13
C-NMR, FT-IR, and MS (ESI)) 
spectroscopy.  
 
The mono-substituted pyrazine derivative A-7 (7) and three of its disubstituted analogues (YAN-
1(18), YAN-2 (19), and YAN-3(20)) were in vitro screened for their biological activity against 
two forms of acute myeloid leukemia cells (Molm-13). The viability of the cells was determined 
using WST-1 assay. Initial results of the tested derivatives showed that A-7 (7) was more potent 
than its analogues with IC50 of 18 and 39 µM against Molm-13 (sh-p53) and Molm-13 (empty 
vector) respectively.  
 
The biological activity of mono and disubstituted pyrazine derivatives was predicted using PASS 
software. Initial results demonstrated that A13 (13), A14 (14), YAN-7 (24), and YAN-8 (25) 
exhibited predicted activities as antineoplastic agents and signal transduction pathway inhibitors 
with relatively high Pa values. The previously mentioned compounds shared also the same 
mechanism of action “protein kinase inhibitor” with Pa values larger than 0.8. 
 
iv 
 
SAR derived from PASS and initial biological activity screening results proved that the activity 
of the synthesized derivative is highly affected by the site and type of the substituent on the 
pyrazine ring. 2,3-disubstituted derivatives showed better Pa values when compared to  the 
corresponding 2,5-disubstituted ones. In addition, amine substituents at positions 2 and 3 of 
pyrazine ring were preferred over alkoxide substituents in terms of antineoplastic activity. It was 
noticed that 1-(5-trifluoromethylpyridin-2-yl)-piperazine and 2-aminopyridine pharmacophores 
were the most active amine substituents. 
 
In order to gain an insight into the binding mode of pyrazine derivatives with CDK-2, a series of 
sixteen derivatives were docked with inactive monomeric cyclin dependent kinase-2 using 
SwissDock software. Results were compared with ‘Aloisine B‟, a well-known CDK-2 inhibitor. 
 
In terms of binding mode, pyrazine derivatives occupied the CDK-2 ATP binding site and made 
hydrogen bonds to the kinase backbone within the hinge sequence that links the two lobes of the 
kinase. The docked derivatives exhibited different binding affinities to the target, YAN-8 (25) 
showed the highest full fitness value (-1422.14 kcal/mol) among the synthesized derivatives. 
Moreover, both the full fitness and energy values indicated that YAN-8 (25) has higher affinity 
to the target in comparison to the known inhibitor Aloisine B (-1406.92 kcal/mol). 
 
Finally, the concept of drug likeness of the synthesized derivatives was investigated using the 
rule of five. Results revealed that all of the tested derivatives successfully met the rule of 5 
requirements except YAN-9 (26) and YAN-10 (27) which possessed molecular weights larger 
than 500 Daltons.  
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Chapter One 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
2 
 
1. Introduction 
      1.1. Background 
The burden of cancer is noticeably increasing worldwide especially in developing countries such 
as Palestine. According to recent statistics published by the Palestinian Ministry of Health in 
October 2016, the total reported cancer cases in west bank were 2536 with higher incidence 
percentage in women (52.4%, 1330 case) than men (47.6%, 1206 case) and a total incidence rate 
of 86.4 per 100,000 of the population. Cancer is considered the second leading cause of death 
proceeded only by cardio and cerebra vascular diseases with approximately 14% of the total 
population deaths. With significant improvement in treatment and prevention of cardio and 
cerebra vascular diseases, cancer will soon become the number one killer in many parts of the 
world. It is predicted that there will be more than 15 million new cancer cases and 12 million 
deaths due to cancer in 2020 all around the globe
[1]
.  
 
Discovery of new drugs for the treatment of cancer has been gaining a great deal of interest 
mainly due to resistance toward conventional chemotherapeutic agents. Furthermore, multidrug 
resistance
[2, 3]
 characterized by resistance not only to drugs that are similar structurally and 
functionally but also cross-resistance to unrelated drugs has also been emerged. Hence, search 
for novel anticancer agents with diverse chemical structures was the need of the hour. 
 
In the last decade, uncountable efforts were made to synthesize different (five, six and seven 
membered, condensed) heterocyclic compounds and their derivatives relying on the fact that they 
possess promising antitumor activities
[4]
. Nitrogen containing cyclic structures has maintained 
the interest of researchers through the development of organic chemistry. For instance, 
substitution of two carbon atoms of the benzene ring by trivalent nitrogen occupying different 
positions of the ring gives rise to “diazines”, with the molecular formula of C4H4N2, which are 
odorous, colorless compounds possessing solubility in organic solvents and relative stability
[5]
. 
The diazine family was considered a promising lead in the field of drugs development because of 
the diverse biological activities endowed by the heterocyclic core itself and by its derivatives as 
well
 [4, 6]
. 
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1.2. Chemistry of pyrazine 
One of the naturally occurring diazines is pyrazine (also known as p-diazine or 1,4-diazine) 
(Figure 1.1 (3)), a 6π-electron-deficient aromatic heterocyclic ring with two nitrogen atoms 
located in the 1 and 4  position of the heterocycle 
[7, 8]
. This ring is isomeric with two other forms  
of diazine, pyridazine and pyrimidine (Figure 1.1 (1, 2)). 
 
 
 
 
 
 
 
Pyrazine is considered a stable, colorless tertiary amine with a boiling point of 116°C and a 
melting point of 54°C. The additional pyridine-like nitrogen highly decreases the basicity of 
pyrazine (pKb = 13.49) in comparison to pyridine (pKb = 8.7), while the symmetrical Para 
position of the electron-attracting nitrogen atoms makes pyrazine a weaker base than its isomeric 
analogous pyrimidine (pKb = 12.77), or pyridazine (pKb = 10.76).
[9]
 In general, pyrazine behaves 
as monoacidic bases protonated at N-1. N, N-diprotonation of pyrazine is difficult and has only 
been observed in very strong acidic media. Pyrazine forms monoquaternary salts with alkyl 
halides which are unstable and are best prepared at temperature below 40°C. Pyrazine also reacts 
with halogenated acids to form pyrazinium salt. 
 
According to an x-ray study, it was shown that the pyrazine ring is planar hexagon. The carbon-
carbon bond length is 1.39Å which is longer than that of benzene, while the carbon-nitrogen 
bond length is 1.34Å. The bond angle (N-C-C) is 121.8° whereas the bond angle (C-N-C) is 
116.3°
[10]
. 
 
One of the very distinct characteristics of pyrazines is that they are electron deficient aromatic 
heterocycles. The nitrogen atoms present in the aromatic ring possess lone pairs which are not 
involved in the aromatic ring π system. Both nitrogens are sp2 hybridized and their lone pairs 
reside in one of the hybridized orbitals.  
Figure 1.1: Structures of diazines, (1) 1, 2-diazine (pyridazine), (2) 1, 3-diazine (pyrimidine), (3) 
1, 4-diazine (pyrazine). 
N
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sp2 orbitals are perpendicular to the un-hybridized p orbitals that form the π system; therefore 
the electrons are unable to participate in the ring‟s π network. This characteristic leads to an 
inductive effect caused by these nitrogens. Instead of increasing ring electron density, they 
decrease it. Nitrogen is more electronegative than carbon, therefore the electron density in the 
ring σ-bonds is unevenly distributed, with partially negative nitrogens and partially positive 
carbons
[11, 12]
. The resonance hybrid of pyrazine is depicted in Scheme 1.1. 
 
Since pyrazine is an aromatic heterocycle, therefore it should undergo aromatic substitution 
reaction. From the forms shown in Scheme 1.1, it can be seen that the electron deficiencies are at 
2, 3, 5 and 6 positions. Therefore, nucleophilic reagents could attack at these positions. However, 
studies have shown that the nucleophiles attacked the ring only if there is at least one powerful 
electron releasing group such as NH2, OH, SH in another position
[13-15]
. During (SNAr) of 
halogenated pyrazine, the nitrogen participates in resonance stabilization of the negatively 
charged anion as shown in Scheme 1.2.  
 
N
N
Nu
x
N
N
Nu
x
N
N
Nu
x
 
  
 
Pyrazine demonstrates unique physicochemical properties that are caused by a low-lying 
unoccupied p-molecular orbital and by the ability to act as bridging ligand or building blocks for 
the construction of multinuclear transition metal complexes, metal-organic frameworks, highly 
luminescent complexes, and catalysts. The inherent bi functionality and the low-lying 
unoccupied molecular orbital permit pyrazine to form coordination polymers having unusual 
electrical and magnetic properties
[16]
.  
Scheme 1.1: The resonance hybrid of pyrazine. 
 
 
 
Scheme 1.2: The resonance stabilization of pyrazine during nucleophilic aromatic substitution. 
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1.3. Prevalence of pyrazine 
1.3.1. Natural pyrazines and pyrazine derivatives 
There are various natural substituted pyrazines. They may carry substituents on one or more of 
the four pyrazine ring carbon atoms including alkoxy, acyl, thiols, or sulfide. Alkylated 
pyrazines are the most abundant form of pyrazine in nature. 
[17, 18] 
 
Some of the naturally occurring pyrazines are found in plants or animals in which  pyrazines play 
the roles of attractants, pheromones, signal substances, repellents and site markers especially in 
insects and bees (Figure 1.2 (4,5,6)). 
 
One of the naturally occurring and biologically active pyrazine alkaloids is Botryllazine b 
(Figure 1.2 (7)) which was first isolated from the red ascidian Botryllus leachi by Duran et al, 
Botryllazine is now synthesized and used as cytotoxic agent.
[19]
 Pyrazines are also 
biosynthesized by a number of fungi and bacteria, examples include the antibiotic aspergillic 
acid and the fungicidal pigment pulcherrimin.
[20]
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Moreover, several approaches for extracting pyrazine out of its natural sources were documented 
in the literature, one of them is the so-called „Maillard reaction‟ which mainly depends on 
heating food to produce pyrazines
[21]
. This reaction was first discovered by Louis Camille 
Maillard in 1912 while attempting to reproduce biological Protein synthesis. 
 
 
Figure1.2: Naturally occurring pyrazine derivatives: 
(4) 2-methyl-6-vinyl-pyrazinefound in beans and wine, (5) 2-isobutyl-3-methoxy-pyrazine 
found in coffee, (6) 2-ethoxy-6-methyl-pyrazine gives pineapple flavor, (7) Botryllazine “b” 
anticancer pyrazine alkaloid. 
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1.3.2.  Synthetic pyrazines 
Although pyrazines occur ubiquitously in nature, they can be synthesized chemically by different 
methods, and are then used as industrial flavoring additives or biologically active substances. In 
general, pyrazine is prepared by the catalytic reaction of diamines with diols in a vapor phase, 
dehydrogenation of piperazine or dealkylation of methyl pyrazine. 
 
Several synthetic methods for pyrazine nucleus have been reported in the literature. In fact one of 
the oldest methods was reported by Staedel-Rugheimer in 1876. In this method, 2-
chloroacetophenone is reacted with ammonia to form the amino ketone which is  then condensed 
and oxidized to form pyrazine (Scheme 1.3 (a)) [22].  
 
Gutknecht extended the field of pyrazine synthesis in 1879, applying self-condensation of 2-
aminoketone, with a slight difference in the way that the alpha-ketoamine is synthesized. The 
ketone was reacted with nitrous acid to form an oximino ketone followed by reduction to an α-
amino ketone
[23]
. Nevertheless the two methods described above result in the formation of 
symmetrical pyrazines (Scheme 1.3 (b)). 
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N
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R
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N R1
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R
R
2NH3 -H2O O
O
a.Staedel-Rugheimer pyrazines synthesis
b.Gutknecht pyrazine synthesis
R
O
N
OH
R
O
N
H
SO3K
CN
N
N R
R
NC
CN
4NaHSO3
2KCN O
2HCl
c.Gastaldi pyrazine synthesis
 
 
Scheme 1.3: Synthetic methods for the preparation of pyrazine derivatives: (a) Staedel-Rugheimer 
method, (b) Gutknecht method, (c) Gastaldi method. 
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The Gastaldi reaction (1921) is another variation that provides alternate use of alpha-oximino-
ketones to afford dicyanopyrazines by cyclization of two molecules of an aminocyanomethyl 
ketone, produced by treatment of an isonitrosomethyl ketone bisulfite with potassium cyanide, 
heating in hydrochloric acid, and oxidation
[24]
 (Scheme 1.3 (c)). As synthetic organic methods 
evolved, simple and efficient pyrazine synthesis pathways emerged, including the preparation of 
pyrazine through the condensation of 1,2-diketones with 1,2-diamine
[25]
, this method can be used 
for both symmetrical and non-symmetrical pyrazine synthesis in good yields (Scheme 1.4 (b)). 
 
Moreover, synthetic methods can vary depending on the planned pyrazine derivatives and they 
have prominently been cited in the literature using different catalytic techniques. For instance, 
the synthesis of pyrazine derivatives by direct conversion of α-hydroxy ketones and α-keto 
oximes in the presence of a catalytic amount of ceric ammonium nitrate was reported by A. 
Shaabani et al
[26]
. While M. Latha et al. synthesized pyrazine from ethylene diamine using 
copper oxide/copper chromite catalysts. The procedure depends on the deaminocyclisation 
(deamination reaction leading to the cyclisation process) of ethylenediamine followed by 
dehydrogenation over copper chromite catalysts which results in the formation of pyrazine with 
greater selectivity (Scheme 1.4 (a)).In this method, ethylenediamine vapor was passed over a 
series of copper oxide/copper chromite catalysts in the temperature range of 340°C-440°C. Two 
molecules of ethylenediamine condensed to form piperazine by releasing two molecules of 
ammonia, which further dehydrogenated to form pyrazine as a major product. 
 
 
 
 
 
 
 
 
 
 
NH2
NH2 NH
H
N
N
N
-2NH3
-3H2
2
H2N
H2NO
O
N
N
-2H2O
O
a. Deaminaocyclisation of ethylenediamine
b. Condensation reaction of 1,2-diketones with 1,2-diamine
Scheme 1.4: Synthetic routes for the preparation of pyrazine derivatives: (a) deaminaocyclisation 
of ethylenediamine, (b) condensation reaction of 1,2-diketones with 1,2-diamine. 
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The formation of pyrazine as the major component suggests the high activity of the copper based 
catalysts to effect spontaneous dehydrogenation of piperazine
[27]
. Another approach was the 
Synthesis of 2-methyl pyrazine from zinc-modified ferrierite catalysts as documented by R. 
Anand et al
[28]
. In addition the application of microwaves in promoting organic reactions has 
received intense attention recently. Microwave-assisted synthesis of pyrazine derivatives from α-
halo ketone in 7% NH3 solution was reported by T. Utsukihara et al
[29]
. While Y.J. Cheng has 
developed an ancillary method for acceleration of nucleophilic aromatic substitution reactions 
under microwave irradiation
[30]
. In this method, the formation of substituted pyrazines were 
obtained by the interaction of 2-chloropyrazine with the nucleophiles of PhSNa, MeSNa, EtONa 
and PhONa in (NMP) which gave the desired substitution products in a good yield of 69 – 96%.  
 
1.4. Importance of pyrazine derivatives 
Pyrazine ring is considered among the important diazines; it is believed that the cytotoxic 
activity of several natural and synthetic heterocyclic compounds is attributed to the presence of 
pyrazine heterocycles. On the other hand, pyrazine occupies an essential part of the systems 
including azine dyes eurhodines (8), safranines (9) and indulenes (10). 
[31-34] 
In addition, this 
heterocyclic ring is part of various compounds that are relevant to biological and industrial use. 
Examples include quinoxalines (11), phenazines (12), bio-luminescent natural products 
pteridines (13), flavins (14) and their derivatives (Figure 1.3). 
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Figure 1.3: Important pyrazine derivatives: (8) eurhodines, (9) safranines, (10) indulenes, (11) 
quinoxalines, (12) phenazines, (13) pteridines, and (14) flavins.  
9 
 
1.5. Therapeutic potential of pyrazine derivatives: literature review 
This section demonstrates some of the substituted pyrazine derivatives along with their diverse 
biological activities including antimicrobial, herbicide, cardiovascular, anti-inflammatory, 
analgesic, and anticancer activities.  
 
     1.5.1. Antimicrobial activity  
Some pyrazine derivatives act as antimicrobial agents and exhibit different activities against 
bacteria, fungi, and mycobacterium species. A well-known derivative of pyrazine is the 
pyrazinamide (Figure 1.4 (15)). It is used as first line drug in tuberculosis treatment. The 
synthesis  of pyrazinamide was first described in 1936 and the discovered molecule was implied 
for  therapeutic use in 1952.
[35]
 Since then many of pyrazinamide analogs have been synthesized 
and evaluated as tuberculostatic agents by introducing structural modifications to the pyrazine 
ring.
[36]
 Foks and his coworkers reported the synthesis of pyrazinamidrazones (Figure 1.4 (16)). 
[37]
 The synthesized compounds exhibited prominent antifungal activity.  
 
      1.5.2. Herbicide activity 
It has been reported that compounds containing the pyrazine fragment as Diquat (Figure 1.4 
(17)), Propaquizafop and Quizalofop-ethyl are very useful herbicides. Other synthetic 
compounds such as substituted N-phenylpyrazine-2-carboxamides and diazachalcones also 
showed remarkable herbicide activity. Some examples are the derivative of 6-chloro-N-(5-
chloro-2-hydroxyphenyl)-pyrazine-2-carboxamide (Figure 1.4 (18)) and the ortho-hydroxyl 
substituted derivatives of chalcones and  diazachalcones (Figure 1.4 (19)). 
[38]
  
 
    1.5.3. Cardiovascular activity 
Stilbene derivatives containing ligustrazinyl moiety (Figure 1.4 (20)) are among the most 
important cardiovascular protective agents. They were synthesized by Deng and his coworkers. 
Most of the derivatives exhibited good protective effects on the oxidatively damaged endothelial 
cells and showed higher potency than Ligustrazine itself. Other pyrazine derivatives showed both 
antioxidative and thrombolytic effects (Figure 1.4 (21)). 
[39] 
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    1.5.4. Anti-inflammatory activity 
A series of pyrazine N-acylhydrazone derivatives were found to have antinociceptive and anti-
inflammatory activities by Da Silva et al. mainly compound (2-N-[(E)-(3,4,5- 
trimethoxyphenyl)methylidene]-2-pyrazinecarbohydrazide (Figure 1.4 (22)) that presented a 
good pharmacological profile and was also active in a murine model of chronic inflammation 
(adjuvant-induced arthritis test in rats). 
[40] 
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    1.5.5. Analgesic activity 
Mirfentanil (Figure 1.4 (23)) is a pyrazine derivative with strong selectivity for the opioid 
receptor. This compound could be produced through many synthetic methods. One of the most 
widely used synthetic route is the use of 4-amino-1-phenethylpiperidine as a starting material to 
obtain 1-phenethyl-4-[N-(pyrazinyl)amino]piperidine followed by acylation with 2-furoyl 
chloride in 1,2-dichloroethane to yield mirfentanil. 
[41]
 
Figure 1.4: Pyrazine derivatives with different biological actvities:  
Antimicrobial activity (15) Pyrazinamide and (16) pyrazinamidrazone, (17, 18, 19) herbicide 
activity, (20, 21) cardiovascular activity, (22) antinflamatory, (23) analgesic mirfentanil.  
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  1.6. Anticancer activity 
Many pyrazine derivatives were synthesized and evaluated as potential anticancer agents 
working against various enzyme targets including protein kinase inhibitors, aurora kinase 
inhibitors, mitotic kinase inhibitors, B-RAF inhibitors, check point kinase inhibitors, A549 lung 
cancer cell inhibitors, mammalian target of rapamycin (mTORC1 and mTORC2) inhibitors, 
caspase-3 inhibitors and activated Cdc42-associated kinase inhibitors, this section illustrates  
some of the main anticancer derivatives along with their targets 
[42, 43]
.  
 
1.6.1. Cytotoxic substituted pyrazine derivatives  
1.6.1.1. Proteasome inhibitor Bortezomib:  
Proteasomes are key regulators of protein degradation, during multiple myeloma it is likely that 
the malignant cells have altered or defective cell cycle proteins leading to an increased 
proliferation rate, increased accumulation of damaged proteins and therefore higher dependency 
on the proteasomal degradation processes
[44]
. As a result inhibition of the proteasome has 
emerged as a clinically effective anti-cancer therapeutic approach over the past decade. The first-
in-class Bortezomib (Figure 1.5 (24)) is a proteasome inhibitor that shows in preclinical studies 
good pleiotropic effects, disrupting multiple cellular signaling pathways and inducing tumor cell 
death. 
[45]
 
 
1.6.1.2. DNA binding 2,6-diphenylpyrazine derivatives:  
DNA remains an attractive target for the design of antitumor agents. Series of bis-phenylpyridine 
derivatives substituted with different side chains, neutral or cationic showed little cytotoxicity 
but their anti-proliferative activity did not correlate with DNA binding. In an extension of this 
work, a new series of molecules for which the pyridine central ring has been replaced with a 
pyrazine ring were synthesized and the DNA binding and cytotoxic properties were investigated 
and directly compared to their pyridine analogs. In all cases the incorporation of the pyrazine 
ring promoted the cytotoxicity of the molecules compared to the corresponding pyridine 
analogues, previously synthesized (Figure 1.5 (25)).
[46]
 
 
1.6.1.3. Cytotoxic Bis (indolyl) pyrazine: 
Series of 3,6-bis(3
'
-indolyl)pyrazine (Figure 1.5 (26)) were synthesized and evaluated for 
cytotoxic activity against diverse human cancer cell lines by the National Cancer Institute. These 
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compounds demonstrated significant inhibitory effects on the growth of a range of cancer cell 
lines. However the mechanism of action remained unknown. 
[47]
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1.6.1.4. B-RAF inhibitors Di-substituted Pyrazine Scaffold: 
The protein kinase B-RAF, is a member of RAF family proteins which are a serine/threonine 
kinases, it plays an important role in the development of certain classes of cancer, especially 
melanoma (50-70%), ovarian (~35%), thyroid (~30%) and colorectal (~10%) cancers. As a result 
of high-throughput screening, the lead compound 2-(3, 4, 5-trimethoxyphenylamino)-6-(3-
acetamidophenyl) pyrazine was identified as a B-RAF inhibitor and was chosen as the starting 
point for producing potent inhibitors of B-RAF. A series of novel compounds, which involved 
extensive modifications to the 2-(3, 4, 5-trimethoxyphenylamino) moiety and their biological 
profiles against isolated B-RAF and mutated B-RAF in a cellular assay have been determined. 
These efforts led to the identification of two compounds exhibiting remarkably enhanced 
activities against B-RAF with IC50 values of 0.79 µM and 0.74 µM, respectively (Figure 1.6 
(27) and (28)).
[48]
 
 
Figure 1.5: Pyrazine derivatives with cytotoxic activities: [(1R)-3-methyl-1-({(2S)-3-phenyl-2-
[(pyrazin-2-ylcarbonyl)amino]propanoyl} amino)butyl] boronic acid  (Bortezomib) (24).  
Comparison between 2,6-diphenylpyrazines (25) and the corresponding pyridine analogues in terms  
of DNA binding and cytotoxic properties. Series of 3,6-bis(3
'
-indolyl) pyrazine derivatives (26). 
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1.6.1.5. Kinase inhibitors V-shaped pyrazine derivatives: 
Most 3-[(2-indolyl)]-5-phenyl-2,6-pyrazine derivatives are well known potential CDK inhibitors. 
New derivatives were synthesized using several Indoles and phenyls in aim to diversify 
substitutions of the pyrazine ring. Kinase assay was conducted for the synthesized derivatives 
and showed that compound (Figure 1.6 (29)) was the most potent inhibitor of CDK5. 
[49]
 
                                                                                                            
1.6.1.6. Mitotic Kinase Inhibitor 
Nek2 which is also called as never in mitosis A-related (NIMA) kinase is a serine/threonine 
kinase which plays crucial role in division of cells. Over expression of Nek2 contributes to 
chromosome instability. This makes Nek2 a promising therapeutic target in cancer treatment. 
Whelligan et al.
[50]
 reported a series of aminopyrazine derivatives that inhibits Nek2 using 
structure based drug design. It was noticed that substitution on piperidine ring of the 
aminopyrazine led to the development of the most active compound (Figure 1.6 (30)) having 
IC50 of 0.23 µM. 
 
1.6.1.7. Check Point Kinase (Chk1) Inhibitor 
Chk1 is a human serine/threonine protein kinase of cell nucleus. During DNA damage process, 
Chk1 is getting activated. Inhibition of Chk1 results in abrogation of arrest in the S and G2 
phases in mitotic apoptosis. Hence, Chk1 inhibitors are considered as important therapeutic 
targets in the treatment of cancer
[51]
. Wang et al. have reported a series of compound containing 
1-(5-chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl) urea as Chk1 inhibitor. Among the series, 
(Figure 1.6 (31)) has been reported to cause S and G2/M phase check point arrest with IC50 of 7 
nM. The modified aromatic urea (Figure 1.6 (32)) carries a hydrophilic moiety i.e. tertiary 
aliphatic amine and showed the best enzymatic activity with IC50 of 3 nM 
[52, 53]
.  
 
1.6.1.8. Caspase-3 inhibitors 
Caspases are cysteine proteases with an aspartate residue at the target cleavage site. These 
enzymes are grouped into 3 subclasses via group I, II and III on the basis of sequence homology 
and substrate specificity. Group III caspases are required for apoptotic cell death. Han et al. 
reported the development of potent and selective caspase-3 inhibitors. Compound (Figure 1.6 
(33)) showed excellent anti apoptotic activities in vitro and in vivo models by inhibiting caspase-
3 with a small IC50 value of 0.006 µM 
[54]
. 
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1.6.2. Cytotoxic fused pyrazine derivatives  
Pyrazine ring has importance in exhibiting various biological activities in association with other 
scaffolds like pyrrole, pyrazole, imidazole, triazole, tetrazole, thiophene, oxazole, pyridine, 
piperidine and piperazine. This section highlights the most prominent cytotoxic fused pyrazine 
systems along with their targets.  
Figure 1.6: Pyrazine based inhibitors of different protein kinases: Disubstituted pyrazine 
derivatives as potent B-RAF inhibitors (27), (28). 3-(6-hydroxyindol-2-yl) -5- (phenyl) pyrazine 
as CDK5 inhibitor (29). 1-[3-Amino-6-(3,4,5-trimethoxy-phenyl)-pyrazin-2-yl]-2,3-dimethyl-
piperidine-4-carboxylic acid as (NIMA) kinase inhibitor (30). 1-(5-chloro-2-alkoxyphenyl)-3-(5-
cyanopyrazin-2-yl) ureas as Chk1 inhibitor (31), (32). 3-(2-{5-tert-butyl-3-[(4-methyl-furazan-3-
ylmethyl)-amino]-2-oxo-2H-pyrazin-1-yl}-butyrylamino)-5-(hexyl-methyl-amino)-4-oxo-
pentanoic acid as caspase 3 inhibitor (33). 
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1.6.2.1. Imidazo[1,2-a]pyrazine derivatives as Aurora kinase inhibitor: 
Aurora kinases are cell cycle regulated serine/threonine kinases that play a key role in regulating 
mitosis. Aurora A and B are frequently overexpressed in various human tumors, including 
carcinomas of the breast, head, neck, ovary and colon. Hence inhibition of aurora is expected to 
impair tumor growth as a result of cell cycle disruption and cell death. The family of imidazo 
[1,2-a]pyrazines (Figure 1.7 (34)) have been gaining attention in drug discovery especially as 
structural analogues of purines. Kerekes
[55]
 and Belanger
[56]
 reported a series of compounds with 
imidazo [1,2-a]pyrazine core as potential aurora kinase inhibitors. Compound (Figure 1.7 (35)) 
has been reported as a lead compound with a promising activity as aurora A and B inhibitor with 
IC50 4 and 13 nM, respectively. Because of the importance of imidazo[1,2-a]pyrazines which 
stems especially from their remarkable anticancer activity and as an extension of the  previous 
works on imidazo[1,2-a]pyrazine some novel 1,3-diarylpyrazino[1,2-a]benzimidazole and 
2,3,6,8-tetraarylimidazo[1,2-a]pyrazine derivatives  were synthesized by Kayagil and 
Demirayak. The cytotoxic effects of the compounds were evaluated in vitro against 
approximately 66 human tumor cell lines derived from 9 neoplastic diseases. Compound (Figure 
1.7 (36)) provided a notable activity. 
[57] 
Other imidazo[1,2-a]pyrazine derivatives like 8-
heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines  were used as modulators of Hsp90 complex 
activity for treating a variety of diseases and disorders such as cancer
[58]
. In addition, 6-aryl-
imidazo[1,2-a]pyrazin-8-ylamines was patented as possible treatment of kinase implicated 
disorders.
[59]
 
 
 
1.6.2.2. Pyrido[2,3-b]pyrazine derivatives: 
A series of 2,3,6-trisubstituted pyrido[2,3-b]pyrazines showed higher activity than 2,3,6-
trisubstituted quinoxaline as potential small-molecule inhibitors of the Wnt/β-catenin signal 
pathway in non-small-cell lung cancer cell (NSCLC) lines. one of the most potent derivatives 
was (Figure 1.7 (37)).
[60] 
 Some derivatives of pyrido[2,3-b]pyrazine (Figure 1.7 (38)) were 
active for  modulation of misdirected cellular signal transduction processes such as tyrosine 
kinases, serine/threonine kinases and/or lipid kinases, especially for the treatment of malignant 
disorders and other disorders based on pathological cell proliferations. Other pyrido[2,3,-
b]pyrazine derivatives  (Figure 1.7 (39)) were used mainly as  inhibitors of TGF-β receptor 
kinases, which can be used  for the treatment of kinase-induced diseases, in particular tumors
[61]
. 
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1.6.2.3. Fused pyrazines as anticancer agents 
Other fused pyrazine-based skeletons that were patented as potent anticancer agents include 
diaminopteridine-benzenesulfonamide (Figure 1.8 (40)) an inhibitor of carbonic anhydrase and 
dihydrofolate reductase, and phenazine (Figure 1.8 (42)) an inhibitor of quinine reductases 1 and 
2, and inducible nitric oxide synthase. In addition, a number of quinoxaline N-oxide derivatives 
were also recognized as potent anticancer agents (Figure 1.8 (41)).
[3]
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 Figure 1.8: Fused pyrazines as anticancer agents (40) diaminopteridine-benzenesulfonamide, 
(42) phenazine, (41) quinoxaline N-oxide. 
 
Figure 1.7: Fused pyrazines as anticancer agents: imidazo [1,2-a]pyrazines (34),  (35), (36). 
pyrido[2,3-b]pyrazines (37), (38), (39). 
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1.6.2.4. Pyrrolo-pyrazine derivatives as protein kinase inhibitors: 
Protein kinase enzyme plays a vital role in the control of cell cycle progression, apoptosis, 
growth and metabolism. It is a well-known potential target for intervention in a number of 
diseases including cancer. The derivatives of pyrrolo[2,3-b]pyrazine are known to be 
biologically active. In addition to having antibronchospastic effect and the ability to inhibit the 
activity of p38 MAP Kinase, the compounds of this class could also inhibit cyclin dependent 
kinases (CDKs) and glycogen synthase kinase-3 (GSK-3), thereby exerting an antiproliferative 
effect. The most known pyrrolo[2,3-b]pyrazine derivatives are aloisines (Figure 1.9 (43))
[62]
. 
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Figure 1.9: Pyrrolopyrazine derivatives as kinase inhibitors. 
 
Dubinina et al. reported a series of compounds containing 5,7-disubstituted 6-amino-5H-
pyrrolo[3,2-b] pyrazine-2,3-dicarbonitrile core as protein kinase inhibitors with anti-proliferative 
activity. Compound (Figure 1.9 (44)) exhibited a significant anti-proliferative activity against 
RXF 393 (renal cancer) and BT-549 (breast cancer) cell lines
 [63]
.
 
Some pyrrolopyrazine 
derivatives were patented as useful inhibitors of ATR protein kinase
[64]
 and showed unexpected 
ability to treat cancer as single agents and exhibited surprising synergistic effect with other 
cancer agents, such as cisplatin (Figure 1.9 (45)). 
 
At the end of this literature review, our main subject of focus was the aloisines as it exerts 
numerous inhibitory activities against different types of protein kinase systems especially the 
cyclin dependent kinase, along with its toxicity against wide panel of cancer cell lines. The next 
section will provide better understanding for the inhibitory activity and selectivity of this class of 
compounds in aim to prepare new pyrazinyl analogues that mimic the binding mode of aloisines 
with good selectivity toward cyclin dependent kinase (CDK). 
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1.7. Cyclin dependent kinase structure and function: 
 
1.7.1. Summary 
Cyclin-dependent kinases (CDKs) are a family of serine/threonine protein kinases whose 
members get activated by binding to their respective cyclin subunits. In most cases, full 
activation also requires phosphorylation of a threonine residue near the kinase active site. To 
date, 13 CDKs and 25 cyclins have been discovered and their biological functions remain 
incompletely understood. CDKs were originally studied for their direct role in cell cycle 
regulation (Figure 1.10 (a)). Cell-cycle events in multicellular eukaryotes are mainly controlled 
by two Cdks, known as Cdk1 and Cdk2, which operate primarily in M phase and S phase, 
respectively. In normal cells, progression from one phase of the cycle to the next can be initiated 
only after passage through checkpoints, where correct completion of the preceding steps, e.g. 
faithful DNA replication at the end of S phase, is verified. If the steps have not been properly 
executed, the cell undergoes apoptosis (programmed cell death). Tumor cells possess faulty 
checkpoints and can proliferate despite a compromised genome. Very often the mechanisms by 
which transformed cells can override checkpoints are closely related to CDK function. For this 
reason, restoration of cell cycle control through pharmacological inhibition of CDKs has been 
actively pursued over the last decade as a new strategy for the treatment of cancer. More 
recently, however, it has become clear that CDKs are involved in many other cellular processes, 
including regulation of transcription, differentiation and cell death. 
[65]
 
 
1.7.2. Kinase structure and binding 
Cyclin dependent kinases (CDKs) are considered small proteins with a size of (~34–40 kDa), 
they are mainly composed of two subunits: The first subunit is the regulatory cyclin subunit 
which is the essential activator of CDKs, it is composed of about 100 amino acids rolled into a 
five-helix bundle, including a highly conserved box. The second subunit is the protein kinase 
catalytic domain, which contains ~250–300 amino acid residues. All CDKs share a common 
tertiary structure comprising two terminal lobes which differ in size: an upper, small amino 
terminal lobe (N lobe) characterized by a β-sheet structure, and a lower, larger carboxy-terminal 
lobe (C lobe) which is commonly α-helical in shape. The variation in the orientation of the two 
lobes yields open and closed conformations. The importance of closed conformation is 
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represented in forming of the ATP binding pocket. The ATP-binding pocket and the active site 
are located between the two lobes of the cleft; ATP fits snugly in that cleft, in such a way that the 
phosphates are oriented outwards toward the cleft mouth. The protein substrate attaches at the 
cleft‟s entrance and interacts with the surface of the C lobe. Subsequently adjacent residues 
catalyze the transfer of the terminal phosphate of ATP to a hydroxyl oxygen in the protein 
substrate.
[66]
 
b
 
 
 
 
 
 
 
 
The structure of the two lobes of the CDKs is the same as other protein kinases, but with some 
structural differences that render them inactive in the absence of cyclin. One of the structural 
differences is that CDKs have a large flexible threonine loop (T loop), also known as the 
activation loop, which is located next to the active site and rises from the carboxy-terminal lobe 
to block the binding of protein substrate at the entrance of the active-site cleft. As a result the 
phosphorylation of this lobe is required to maximize kinase activation. Another structural 
difference is that in the case of inactive CDKs the active site residues (amino acid side chains) 
are not positioned properly, preventing ATP phosphate group from getting ideally oriented. 
Correspondingly proper enzyme activation requires massive structural changes in the active site 
Figure 1.10: a) The CDKs responsible for progression through the various phases of the cell division 
cycle are indicated. CDK7 (CDK-activating kinase, CAK) is involved in activation through 
phosphorylation of both CDKs 1 and 2.   b)  Tertiary structure of human CDK2, determined by X-ray 
crystallography. The structure of CDK2 is composed of two parts: first part is the amino-terminal lobe 
which is composed of beta sheet structure (red color) and the PSTAIRE helix, second part is the carboxy-
terminal lobe which is mainly composed of alpha helices (blue color). The ATP binding pocket and active 
site are located within the two lobes. The Helix L12 and T-loop are shown in green color. 
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of CDK. The activity of CDK is mainly controlled by the contribution of two alpha helixes; the 
first one is the PSTAIRE helix (an alpha helix close to the N lobe of CDK) which interacts with 
cyclin subunit. The movement of PSTAIRE helix reorients the residues that interact with the 
phosphate group of ATP in a way resulting in kinase activation, the second helix is the L12 helix 
(small alpha helix close to T-loop) changes its structure upon cyclin binding to become a beta 
strand, and contributes to the reconfiguration of the active site and T-loop. (Figure 1.10 (b)) 
shows the structure of a protein kinase 2 catalytic domain. 
[66]
 
 
1.7.3. Cyclin-dependent kinase activation: 
The activation of CDKs is achieved by two steps. The first step 
is triggered  by the binding of the cell synthesized protein 
cyclin with its corresponding  CDK (Figure 1.11). 
[59]
 
[58] 
The 
second step is phosphorylation of threonine160 on the CDKT-
loop. This step is mediated by CDK activating kinase (CAK). 
Therefore, the phosphorylation step leads to a change in the 
CDK‟s active site conformation.  Afterwards the T-loop moves 
from the entrance point of the active site reducing the steric 
hindrance that blocks the binding site. CDK2 activation 
transfers the cell into the next phase of the cell cycle.
 [66]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
b
c
d
Figure 1.11: schematic structure of CDK2 in various states of 
activity. a) The inactive CDK2 monomer, the small L12 helix next to 
T loop pushes out the large PSATAIRE helix which contains 
glutamate 51, the T-loop blocks the active site cleft. b) When cyclin A 
binds to CDK2 the PSATAIRE helix moves inward and the L12 
changes structure to form a small beta strand, E51 moves inward to 
interact with lysine33 while aspartate 145 also shifts position. These 
changes lead to the correct orientation of the ATP phosphate .The T 
loop also shifts out of the active site entrance. c) The phosphorylation 
of threonine 160 causes the T loop to flatten and interact more 
extensively with cyclin A. d) phosphorylation allows T loop to 
interact effectively with a protein substrate containing SPXK sequence 
(pink), a number of interactions occurs so the substrate is positioned in 
a correct way for nucleophilic attack on the phosphate of the ATP. 
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Once the cell has moved into the next phase, the CDK is 
deactivated by adding phosphate group to the two sites in G-
loop, which are threonine (T14) and tyrosine (Y15) as shown 
in (Figure 1.12). 
[66, 68]
 
Figure 1.12: View of CDK2/ATP (1HCK coordinates taken from PDB 
database) complex is shown in tube representation. The T160 (shown in 
gray-colored licorice representation) activation site is located on the T-
loop. The G-loop (black-colored tube representation) includes two possible 
inhibitory sites, T14 (gray-colored licorice representation) and Y15 (black-
colored licorice representation). 
 
1.7.4. Cyclin-dependent kinase inhibition  
Regulation of CDK activation and inhibition is a key component in controlling the cell cycle. 
Any changes in CDK activity would create errors in the cell cycle. This can lead to the 
uncontrolled cell growth and division, giving rise to cancerous cells. Scientist propose that 
inhibition of abnormal cell proliferation might be possible through the inhibition of CDKs. CDK 
inhibitors, therefore, are biologically interesting targets to design, synthesize and study as 
potential anti-cancer agents. Because of the clear connection between pharmacological CDK 
inhibition and cell cycle regulation, the potential use of CDK inhibitors in oncology was 
appreciated some time ago and the first molecules are now undergoing clinical evaluation. 
[69, 70] 
 
1.7.5. Mode of action  
The inhibition of CDK can be done using different inhibitors that bind to the cyclin-CDK 
complex and inactivates it. These molecules result in promoting cell cycle arrest in G1 phase. 
The great majority of known CDK inhibitors are ATP-competitive type, interacting with cyclin-
dependent kinases within their catalytic ATP-site. Until now, this strategy has been the most 
successful in designing inhibitors of CDKs. On the other hand, ATP Non-Competitive Inhibitors 
are a new inhibitors-generation which does not enter in competition with ATP, therefore 
exhibiting an action mode different from the other type of inhibitors. Nowadays two classes of 
ATP non-competitive CDKs inhibitors have been identified: Small Molecules Inhibitors and 
Small Peptide Inhibitors which are peptides designed based on their similarity with endogenous 
CDKs inhibitors. Moreover, Allosteric Inhibitors bind CDKs away from their ATP-binding site. 
Resulting in a conformational change to the CDKs, thus modifying their activity.
[71]
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1.8. Pyrrolopyrazines as kinase inhibitor:  
1.8.1.  Binding and structure activity relationship 
As mentioned earlier, the most recently reported pharmacophore with high CDK potency and 
selectivity encompasses compounds containing the 6-phenyl[5H]pyrrolo[2,3-b]pyrazine core 
structure (Aloisines), the conserved substructure of these compounds is shown in (Figure 1.13). 
Aloisines are selective inhibitors of CDK1, CDK2, CDK5 and GSK3. The most potent aloisine 
so far is aloisine A, with reported IC50 values of 0.15 μM (CDK1),  0.12 μM (CDK2/cyclin A), 
0.16 μM (CDK5) and 1.5 μM (GSK3β) in functional kinase assays, on the other hand Aloisine A 
is less potent against ERK1 (IC50 = 18 μM) and ERK2 (IC50 = 22 μM). This concludes that 
aloisines are less potent towards ERKs; however the understanding of SARs suggests that this 
pharmacophore might lend itself to the design of inhibitors with differential selectivity 
profiles.
[72]
 
 
 
 
 
 
 
Figure 1.13: structures of Aloisine A (47): (4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol) 
and Aloisine B (48): (6-(4-Chloro-phenyl)-7-isopropyl-5H-pyrrolo[2,3-b]pyrazine 
First, to investigate the mechanism of aloisine‟s action, kinetic studies were performed by 
varying both ATP levels and aloisine A concentrations. These experiments were performed with 
CDK1/cyclin B, CDK5/p25, and GSK-3â. The data demonstrates that aloisine act by competitive 
inhibition of ATP binding to the catalytic subunit of the kinase. The resolution of a CDK2-
aloisineB cocrystal structure was in agreement with these findings. (Figure 1.14) illustrates the 
interactions between aloisine B and the CDK2 ATP-binding site. As observed, aloisine occupies 
the ATP-binding pocket and makes two hydrogen bonds with nitrogen and oxygen atoms of Leu 
83 amino acid which lies within the hinge region sequence that links the two lobes of the 
kinase.
[72]
 
An examination of the key features responsible for the potency and selectivity of known 
inhibitors of CDK, GSK3β and ERK2 can be used as a guide in the design of new inhibitors. 
Pharmacophore maps of the ATP-binding sites show that there are two main criteria that need to 
N
N
H
N
R2
R1
1
45
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c
d e
(46)
(47) (48)
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be met in order to yield compounds that have affinity for the ATP-binding pocket: the 
compounds need to bind effectively to the hinge region, through two or three H-bond donor or 
acceptor groups, and there must be sufficient hydrophobic interactions within the adenine-
binding domain through two or more aromatic ring systems.  
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Secondary 
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as the three nitrogen atoms of the phenylpyrrolo[2,3-b]pyrazine skeleton are engaged in 
hydrogen bonds with the Leu83 and Lys33 residues of CDK2 , substitutions on these three 
positions are to be excluded. Furthermore, replacement of any of the nitrogen atoms in this 
skeleton by a carbon diminishes the inhibitory activity of the resulted compound. As a result, 
substitutions on other positions were undertaken to orientate the synthesis of derivatives toward 
improved CDK and GSK-3 inhibitory activity. 
 
Figure 1.14: The binding of aloisine B to CDK2. a)Schematic representation of the interaction between 
aloisine b and the amino acids in the ATP binding site( hydrogen bonds are represented by dotted line. b) 
Stereoview showing the interactions between aloisine B and the CDK2 ATP-binding site. Residues that 
lie within 4 Å of the bound aloisine B molecule are drawn in ball-and-stick mode. Aloisine B carbon 
atoms are drawn in cyan and those of CDK2 in green. Oxygen atoms are colored red, nitrogen atoms blue, 
and the chlorine atom yellow. Dotted lines represent hydrogen bonds between aloisine B and the 
backbone nitrogen and oxygen atoms of Leu83. c) CDK2 is drawn in ribbon representation and color-
ramped from blue to red, starting at the N-terminus. The N-terminal lobe is dominated by a five-stranded 
antiparallel β-sheet, and the C-terminal lobe is predominantly α-helical. Aloisine B is drawn in ball-and 
stick mode bound at the ATP-binding site, which lies in the cleft between the two domains. Aloisine B 
carbon atoms are colored cyan, nitrogen atoms blue, and the chlorine atom yellow.  
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1.8.2.  Designing selective CDK inhibitors 
Many small-molecule CDK inhibitors have also been found to inhibit certain other kinases. 
Considering the fact that the human genome encodes around 800 protein kinases, these 
observations are hardly surprising. Many ATP antagonist kinase inhibitors previously thought to 
be selective were, in fact, later found to be less than selective when assayed against a large panel 
of functionally diverse kinases. CDKs are phylogenetically closely related to extracellular signal-
regulated kinases (ERK-1 and ERK-2), as well as to glycogen synthase kinase-3 (GSK-3). These 
latter enzymes are frequently also affected by CDK inhibitors. In particular, many CDK2 
inhibitors, including aloisines, are practically equipotent against GSK-3. The structural basis for 
rationalizing inhibitor selectivity for individual CDKs is still comparatively weak, since only 
CDK2-inhibitor complex X-ray co-crystal structures have so far been obtained, whereas other 
CDKs have not so far proven amenable to crystallization.
[73]
 
 
Assuming that aloisine A (a) binds to ERK2 in a similar fashion as to CDK5, the observed 
hydrogen bonds (H-bonds) with the kinase hinge region involve N4 and N5-H of the 
pyrrolopyrazine system for aloisine A (H-bonds indicated by broken lines). The n-butyl chain is 
not well resolved in the crystal structure, which suggests that there is a high degree of freedom of 
movement associated with this alkyl chain. The phenol hydroxyl is directed out of the binding 
pocket and makes suboptimal interactions with surface-specific residues. Whereas substitution at 
both positions b and d (panel a) with either chloro or methoxy resulted in loss of activity, 
monosubstitution at position a, b or c with OH and OMe was productive. Selectivity can 
apparently be controlled through the choice of substituents at position c on the aryl ring. Thus, 
large hydrophobic groups favor GSK3 and CDK1 versus CDK5, whereas small groups such as 
fluoro, methyl and cyano improve potency towards CDK5 without a significant gain in 
selectivity. The reduced potency of aloisine A with respect to ERK1 and ERK2 can be 
rationalized in terms of the less favorable interaction between the polar gate-keeper residue 
(Q103ERK2) and the pyrazine system of the ligand (panel d) as compared to hydrophobic 
interactions for CDK5 and GSK3β (F80CDK5, L132GSK3β ). Moreover linear planar ligands 
are poorly tolerated by ERK2 as the length of the binding pocket is about 2 Å shorter than that of 
CDK5, as measured from the gate-keeper residue (F80CDK5, Q103ERK2) to the surface-
specific Lys residue (K89CDK5, K112ERK2) (Figure 1.15 (a-c)). 
[65]
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Despite the chemical similarity, between aloisines and ERK2- selective inhibitors, the binding 
pose of these compounds in the kinase ATP-binding site does not seem to be related to that of the 
aloisines. Unlike practically all other known CDK–GSK3β–ERK inhibitors, which tend to be flat 
molecules, ERK2- selective inhibitors contains fused mutli heterocyclic systems that allows the 
formation of a highly complementary interaction with the unique features of the ERK2 ATP-
binding pocket. In addition, unsubstituted phenyl group optimally occupies a small hydrophobic 
pocket adjacent to the gate-keeper residue in ERK2; this pocket is smaller in CDK5 and 
practically absent from GSK3β (Figure 1.15 (d-f)). [65] 
Figure 1.15: Pharmacophore maps of CDK5, GSK3β and ERK2 (a-c) .The main residues 
lining the ATP-binding pocket of the three kinases are shown as stick models and the 
prominent pharmacophore features that have yielded potent inhibitors of each kinase are 
indicated with mesh spheres. Regions that are occupied by hydrophobic and aromatic portions 
of these inhibitors are depicted as green spheres and those where inhibitors commonly display 
H-bond donor and acceptor functions are in red and blue, respectively. 
Binding of pyrrolopyrazine to CDK5, GSK3β and ERK2 (d-f). Inhibitors and proteins 
shown as grey CPK space-filling models and mesh surfaces, respectively). Structures are 
modelled from PDB (Protein Data Bank).  
 
 
d e f
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1.9. Pyrazine containing drugs in clinical use 
 
Substituted pyrazines have been successfully introduced to clinical application with wide range 
of activities. The table below summarizes the structures of these drugs along with their 
pharmacological activities. [42] 
 
Table 1.1: List of marketed pyrazine containing drugs along with their biological activity.  
 
number Compound name structure 
Pharmacological 
activity 
(15) Pyrazinamide  
 
N
N
O
NH2
 
Antitubercular
[74]
 
(49) Flutimide 
 
N
N
O O
OH  
Antiviral
[75]
 
(50) Favipiravir 
 
N
N
O
NH2
OH
F
 
Antiviral
[76]
 
(51) 
Pyrazine  
diazohydroxide 
 
N
N
H
N
N
O
 
Antineoplastic
[77]
 
(52) 
Acipimox 
 
 
N+
N
O
OH
O-
 
Hypolipidemic 
agent
[78]
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(53) 
Sulfalene 
 
S
O
O
H
N
N
N
O
H2N  
Antibacterial 
sulfonamide
[79]
 
(54) Glipizide N
N
ON
H
S
O
O
H
N
H
N
O
 
Hypoglycemic 
agent
[80]
 
,Angiogenesis  
inhibitor
[81]
 
(55) Bortezomib 
 
H
N
O
HN
O
N
N
B
OH
OH
 
Proteasome 
inhibitor
[82]
  
(multiple 
myeloma) 
(23) Mirfentanil 
 
OO
N
N
N
N
 
opioid receptor
[41]
 
(56) 
Varenicline 
 
HN
N
N
 
Smoking 
cessation
[83]
 
(57) Amiloride 
 
N
N
O
N
H2N
NH2
Cl
H2N NH2  
Diuretic
[84]
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(58) Telaprevir 
 
 
N
O
HN
O
O
N
H
O
N
H
O
HN
O
N
N
HH
 
Protease inhibitor 
(hepatitis c)
[85]
 
(59) Elpetrigine 
 
N
N
H2N NH2
Cl
Cl
Cl
 
Antiepileptic, 
sodium and 
calcium channel 
blocker
[86]
 
(60) Eszopiclone 
 
N
N
O
O
N
N
N
O
N
Cl
 
Non-
benzodiazepine 
sedative 
hypnotic
[87]
 
(61) 
Oltipraz 
 
 
S
S SN
N  
Antischistosomal 
agent , 
Chemoprotective 
agent
[88]
 
 
(62) Brimonidine 
 
N
N
H
N N
HN
Br
 
Antiglaucoma 
agent 
A2 adrenergic 
agonist
[89]
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Aims and objectives of the study  
 Main objective of the study 
The main objective of this study is to explore the possibility of designing novel pyrazine based 
molecules endowed with cytotoxic activity. The study is based on the design and preparation of 
2,3-disubstituted pyrazine derivatives that will possibly exert activity against cancer cell lines by 
acting mainly as cyclin dependent kinase inhibitors. 
 
 
Specific objectives of the study 
a. To synthesize a series of novel 2,3-disubstituted pyrazine derivatives. 
b. To explore different synthetic strategies that affords the final compounds in shorter time 
and higher yields. 
c. To characterize the synthesized compounds using available physical methods such as 
Fourier Transform Infrared spectroscopy (FT-IR), nuclear magnetic resonance (NMR) 
and mass spectroscopy (MS). 
d. To evaluate the cytotoxic activity of a set of the synthesized derivatives. 
e. To predict the possible biological activities of the newly synthesized compounds using 
PASS software. 
f. To investigate the drug likeness of the synthesized derivatives according to the rule of 
five. 
g. To gain insight into the binding mode and affinities of the synthesized derivatives with 
inactive monomeric CDK-2 using SwissDock software. 
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Chapter Two 
 
 
Experiments and methods 
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2. Experiments and methods 
2.1. Synthetic chemistry 
 
2.1.1. Materials: 
2,3-dichloropyrazine, ethanol amine, phenylenediamine, 4-aminophenol, 4-aminobenzoic acid, 
phenol, 2-methylamino-ethanol, glycine, 2-aminopyridine, 2-piperazin-1-yl-ethanol, 2-piperazin-
1-yl-ethanol, [1,4']pipiperidinyl, 2-piperazin-1-yl-pyrimidine, 1-(3-trifluoromethylpyridin-2-yl)-
piperazine, 1-(5-trifluoromethylpyridin-2-yl)-piperazine, ethylenediamine, sodium, paracetamol, 
N-bromosuccinimide (NBS),  tetrahydrofuran (THF), dicyclohexylcarbodiimide (DCC), N-
hydroxysuccinimide (NHS), sodium sulfate (Na2SO4), diisopropylethylamine (DIPEA), 
potassium carbonate (K2CO3), calcium chloride (CaCl2), potassium bromide (KBr), 
dimethylformamide (DMF), dichloromethane (DCM), ethyl acetate (EA), dioxane, ether,  
triethylamine (TEA), methanol (MeOH), ethanol (EtOH), hexane, isopropanol, chloroform 
(CHCl3) and hydrochloric acid (HCl) were purchased from ACROS chemical Ltd or D-Chem 
and were used without further purification. 
Silica gel (silica gel 60 (0.040-0.063 mm)), thin layer chromatography (TLC) (TLC silica gel 60 
F254) sheets were all purchased from Merck Ltd. 
Deuterated solvents: D2O, CDCl3, DMSO-d6 were purchased from ACROS chemical Ltd. 
 
2.1.2. Instrumentation 
2.1.2.1. Nuclear magnetic resonance (1H-, 13C- NMR):  
Data were collected using Varian Unity Inova 500 MHz spectrometer equipped with a 5-
mm switchable probe and data were processed using the VNMR software. 1H-NMR 
chemical shifts are reported in parts per million (ppm, δ) downfield from 
tetramethylsilane (TMS). Spin multiplicities are described as s (singlet), d (doublet), dd 
(double doublet), t (triplet), q (quartet), and m (multiplet).  
 
2.1.2.2. Fourier transform infrared spectroscopy (FTIR):  
All infrared spectra were obtained from a KBr matrix (4000–400 cm-1) using a Perkin-
Elmer spectrum 100, FT-IR spectrometer.  
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2.1.2.3. Electrospray ionization mass spectrometry (ESIMS):  
Mass spectroscopy was performed using a Thermo Quest Finnigan LCQ-Duo in the 
positive ion mode. Elution was in a mixture of 49:49:2 water/methanol/acetic acid at a 
flow rate of 15 μL/minute. 
 
2.1.3. Synthesis of (2-amino-3-chloropyrazine) derivatives under basic condition 
To a solution of 2,3-dichloropyrazine (0.5ml, 4.803 mmol) in dioxane or tetrahydrofuran (20 ml), 
DIEA (0.744 g, 5.763 mmol) or TEA (0.583 g, 5.763 mmol) was added. The mixture was stirred 
at room temperature for 10 minutes followed by the addition of the corresponding aliphatic or 
aromatic amine (4.803 mmol).While being stirred, the mixture was heated under reflux for 9-12 
hour. The completion of the reaction was monitored by TLC (ethyl acetate: CHCl3; (50:50 v/v)). 
Upon reaction completion volatiles were evaporated under vacuum. Afterwards, the residue was 
extracted against ethyl acetate and water (3 x 30 ml), the combined organic extracts were dried 
over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by 
recrystallization or silica gel column chromatography using (CHCl3: hexane) as eluent to give 
the 2-amino-3-chloropyrazine in 77-91.8 % yield. 
 
 
2.1.3.1.  2-(3-Chloropyrazin-2-ylamino)-ethanol {A1 (1)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.26; dark brown oil, 0.764g; yield = 91.8%. 
1
H-NMR 300 MHz (DMSO-d6, δ ppm): 7.98(d, 1H pyrazine), 7.53(m, 1H pyrazine), 6.86(s, 1H 
amine), 4.75(t, 1H hydroxyl), 3.50(m, 2H), 3.41(m, 2H). 
 
2.1.3.2.  2-[(3-Chloropyrazin-2-yl)-methyl-amino]-ethanol {A2 (2)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.30; light orange oil, 0.798g; yield = 88.9%. 
1
H-NMR 300 MHz (DMSO-d6, δ ppm): 8.13(d, 1H pyrazine), 7.81(d, 1H pyrazine), 4.66(t, 1H 
hydroxyl), 3.58(m, 4H), 3.02(s, 3H CH3). 
 
2.1.3.3.  (3-Chloropyrazin-2-ylamino)-acetic acid {A3 (3)} 
TLC (EA), Rf = 0.08; light brown powder, 0.741g; yield = 82.6%. 
1
H-NMR 300 MHz (DMSO-d6, δ ppm): 8.17(d, 1H pyrazine), 7.85(d, 1H pyrazine), 7.76(t, 1H 
amine), 4.16(d, 2H CH2-NH). 
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2.1.3.4.  (3-Chloropyrazin-2-ylamino)-acetic acid methyl ester {A4 (4)} 
TLC (EA), Rf = 0.12; pale yellow powder, 0.843 g; yield = 87.4%. 
1
H-NMR 300 MHz (DMSO-d6, δ ppm): 8.23(d, 1H pyrazine), 7.89(d, 1H pyrazine), 7.76(t, 1H 
amine), 4.20(d, 2H CH2-NH), 3.58(s, 3H CH3). 
 
2.1.3.5. Butyl-(3-chloropyrazin-2-yl)-amine {A5 (5)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.55; light orange oil, 0.685 g; yield = 77.2%. 
1
HNMR 300 MHz (DMSO-d6, ∂ ppm): 7.96 (d, 1H pyrazine), 7.48 (d, 1H pyrazine), 7.00 (s, 1H 
amine), 3.30 (m, 2 H), 1.49 (m, 2H), 1.29 (m, 2H), 0.85 (tt, 3H CH3)   
 
2.1.3.6. 2-(3'-Chloro-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-ethanol {A6 (6)} 
TLC (EA), Rf = 0.07; beige powder, 0.959g; yield = 82.4 %. 
1
H-NMR 300 MHz (DMSO-d6, δ ppm): 8.25(s, 1H pyrazine), 7.97(d, 1H pyrazine), 4.46(t, 1H 
hydroxyl), 3.51(m, 2H), 3.36(d, 4H piperazine), 2.55(m, 4H piperazine), 2.43(t, 2H) 
 
2.1.3.7.  3’-Chloro-4-(5-trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro-2H[1,2’] 
bipyrazinyl {A7 (7)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.84; white yellowish crystals, 1.417g; yield = 86.1 %. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.43(s, 1H CH-pyridine), 8.28(d, 1H pyrazine), 8.02(d, 
1H pyrazine), 7.82(dd, 1H), 7.00(d, 1H), 3.78(dd, 4H piperazine), 3.48(dd, 4H piperazine). 
13
C-NMR (DMSO-d6, δ ppm): 162.49(C), 156.58(C), 144.7 (CH), 139.24 (C), 139 (CH), 137.71 
(CH), 131.53 (CH), 123.79 (C), 123.31 (C), 107.87 (CH), 48.91 (CH2), 44.28 (CH2). 
FT-IR (KBr) (cm-1): 2863.2 Ar-H (C-H stretch), 1617.62 & 1569 aromatic (C=C) and (C=N) 
stretching, 1498.45 (C-H) bending, 844.3& 787.96 Ar-H (CH2=CH2 bending), 808.15 (C-Cl) 
stretch, 706.78 (C-F) stretch. 
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Figure 2.1: Chemical structure of {A7 (7)} 
 
Table 2.1: NMR data for compound {A7 (7)} 
 
Position 
1
H-NMR 
13
C-NMR 
1 8.29(d,1H) 137.71 (CH) 
2 8.02(d,1H) 139 (CH) 
3 - 139.24 (C) 
4 - 156.58 (C) 
5,5' 3.79(m,4H) 48.91 (CH2) 
6,6' 3.48(m,4H) 44.28 (CH2) 
7 - 162.49 (C) 
8 7.00(d,1H) 107.87 (CH) 
9 7.83(dd,1H) 131.53 (CH) 
10 - 123.79 (C) 
11 8.43(d,1H) 144.7 (CH) 
12 - 123.31 (C) 
 
Table 2.2: FTIR data for compound {A7 (7)} 
 
 
Type of bond Wave number (cm
-1
) 
Ar-H (C-H stretch) 2863.2 
aromatic (C=C) stretching 1617.62 
aromatic (C=N) stretching 1569 
(C-H) bending 1498.45 
Ar-H (CH2=CH2 bending) 844.3& 787.96 
(C-Cl) stretch 808.15 
(C-F) stretch 706.78 
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2.1.3.8. 3'-Chloro-4-(3-trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro- 
2H-[1, 2’] bipyrazinyl {A8 (8)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.80; light orange crystals, 1.284g; yield = 78 %. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.54(d, 1H CH-pyridine), 8.28(s, 1H pyrazine), 8.08(d, 
1H), 8.01(s, 1H pyrazine), 7.22(m, 1H), 3.49(d, 4H piperazine), 3.33(s, 4H piperazine). 
 
2.1.3.9. 3'-Chloro-4-pyrimidin-2-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl {A9 (9)} 
TLC (EA), Rf = 0.08; yellow powder, 1.135g; yield = 85.7 %. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.38(d, 2H pyrimidine), 8.33(d, 1H pyrazine), 8.01(s, 1H 
pyrazine), 6.65(t, 1H), 3.88(s, 4H piperazine), 3.43(s, 4H piperazine). 
 
2.1.3.10. 3'-Chloro-4-pyridin-4-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl {A10 (10)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = =0.71; off-white crystals, 1.074g; yield = 81.4 %. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.34(d, 1H pyrazine), 8.15(d, 2H pyridine), 8.00(d, 1H 
pyrazine), 6.97(m, 2H), 4.14(m, 4H piperazine), 2.89(m, 4H piperazine). 
 
2.1.3.11. 1'-(3-Chloropyrazin-2-yl)-[1,4']bipiperidinyl {A11 (11)} 
TLC (EA), Rf = 0.17; off white crystals, 1.145g; yield = 85.2 %. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.22(d, 1H pyrazine), 7.94(d, 1H pyrazine), 3.90(d, 2H), 
3.34(s, 2H), 2.80(t, 2H), 1.80(d, 3H), 1.46(m, 10H) 
 
2.1.3.12. Synthesis of 7-(3-chloropyrazin-2-yl)-7H-purin-6-amine {A12 (12)} 
To a solution of 2,3-dichloropyrazine (0.5ml, 4.803 mmol) in dioxane (15 ml), (0.730g, 5.283 
mmol) potassium carbonate (K2CO3) was added. Afterwards, adenine (0.648g, 4.803 mmol) 
previously dissolved in DMF (3ml) and water (1ml) was gradually added to the mixture.  The 
reaction was heated under reflux for approximately 16 hour. Reaction completion was confirmed 
using TLC (ethyl acetate: CHCl3; (50:50 v/v)). Upon reaction completion volatiles were 
evaporated under reduced pressure and the residue was extracted against ethyl acetate (3 x 30 
ml). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated. 
For further purification the residue was recrystallized using isopropanol and filtered out leaving 
the desired product.  
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TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.25; yellow powder, 0.978g; yield = 82.48 %. 
 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.76 (m, 2H imidazole and pyrazine), 8.12 (d, 1 H 
pyrazine), 7.54 (s, 1H), 6.75 (s, 2H amine) 
 
2.1.4. Synthesis of (2-amino-3-chloropyrazine) derivatives under acidic condition 
To a solution of 2,3-dichloropyrazine (0.5ml, 4.803 mmol) in dioxane or tetrahydrofuran (20 ml), 
HCl 12.1M (9.606 mmol) and the corresponding aromatic amine (9.606 mmol) were added 
respectively. While being stirred, few drops of distilled water were added into the round bottom 
flask to aid salt solvation. The mixture was heated to reflux for 2-8 hours. Reaction completion 
was monitored by TLC (ethyl acetate: CHCl3; (50:50 v/v)). Upon reaction completion, if a 
precipitate formed the mixture was concentrated and carefully filtered out using suction 
filtration. If no or little precipitate was formed the volatile components of the mixture were 
evaporated to dryness under vacuum, and the residue was extracted against ethyl acetate (3 x 30 
ml). pH adjustment was made to liberate the compound from its salt form; the organic layer was 
then pooled, dried using sodium sulfate, and evaporated to afford the desired 2-amino-3-
chloropyrazine in 84-93% yield. 
 
 
2.1.4.1. N-(3-Chloropyrazin-2-yl)-benzene-1,4-diamine {A13 (13)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf =0.14; brown powder, 0.986g; yield = 93.4%. 
 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 7.97(d, 1H pyrazine), 7.44(s, 1H amine), 7.33(d, 1H 
pyrazine), 6.81(m, 2H benzene), 6.22(m, 2H benzene), 4.69(s, 1H amine). 
 
2.1.4.2.  (3-Chloropyrazin-2-yl)-pyridin-2-yl-amine {A14 (14)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.4; green oil, 0.830g; yield = 84%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.27 (d, 2H pyrazine and pyrimidine), 7.89 (dd, 2H 
pyrazine and pyrimidine), 7.04 (d, 1H), 6.80 (t, 1H), 3.48 (s, 1H amine). 
 
2.1.4.3. 4-(3-Chloropyrazin-2-ylamino)-benzoic acid {A15 (15)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.07; yellow-orange powder, 1.03g; yield = 86.9%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.39(d, 1H), 8.04(m, 3H), 7.73(d, 2H), 4 (s, 1H amine). 
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2.1.4.4. 4-(3-Chloropyrazin-2-ylamino)-phenol {A16 (16)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.26; yellowish green powder, 0.934g; yield = 88.1%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 7.34(d, 2H), 6.81(m, 3H), 6.57(d, 1H), 6.22(s, 1H 
hydroxyl), 3.99 (s, 1H amine). 
 
2.1.5.  Synthesis of mono-alkoxy substituted pyrazine derivatives 
To a stirred solution of potassium carbonate (0.796 g, 5.763 mmol) in dioxane (10 ml), the 
corresponding alcohol acetaminophen (4.803mmol) was added and the mixture was stirred at 
ambient temperature for 30 minutes. 2,3-dichoropyraizne (0.5ml,4.803mmol)  was then added 
and the mixture was heated to reflux for 7 hours. Reaction completion was monitored by TLC 
with a suitable elution system of (ethyl acetate: CHCl3; (50:50 v/v)). Upon reaction completion 
the solution was evaporated to dryness under vacuum and extracted against ethyl acetate and 
water. The combined organic extracts were pooled, dried over sodium sulfate and concentrated. 
The residue was chromatographed on a silica gel column with a mixture of hexane and CHCl3 to 
afford A17 (17) as white powder with 95% yield. 
 
2.1.5.1. N-[4-(3-Chloropyrazin-2-yloxy)-phenyl]-acetamide {A17 (17)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.33; white powder, 1.206g; yield = 95.3%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 10.02(s, 1H amide), 8.16(m, 2H pyrazine), 7.61(d, 2H), 
7.15(d, 2H), 2.03 (s, 3H CH3).  
 
2.1.6. Synthesis of 2-amino-3-alkoxypyrazine derivatives  
YAN-1 (18) and YAN-2 (19): In a 25 ml round bottom flask equipped with a stirring bar, sodium 
(0.133 g, 5.818 mmol) was dissolved in the desired alcohol (10 ml) and the mixture was stirred at 
ambient temperature for 30 minutes. Afterwards, 2,3-dichloropyraizne derivative {(A7), 7} (0.5 
g, 1.454 mmol) was added. The reaction mixture was heated to reflux for 12 hours under calcium 
chloride. Reaction completion was monitored by TLC (ethyl acetate: CHCl3; (50:50 v/v)). Upon 
reaction completion the solution was evaporated to dryness under vacuum and extracted against 
ethyl acetate (3 x 30 ml). The organic phase was dried over sodium sulfate and concentrated. 
Finally the crude was washed with ether and air dried to afford the desired pure product YAN-1 
(18) and YAN-2 (19) in high yields. 
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2.1.6.1.  3'-Ethoxy-4-(5-trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro- 
2H-[1,2']bipyrazinyl {YAN-1 (18)}  
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.81; white powder, 0.498g; yield = 97%.  
1
H-NMR 300 MHz (DMSO-d6, δ ppm): 8.42(s, 1H), 7.81(dd, 1H), 7.75(d, 1H pyrazine), 7.60(d, 
1H pyrazine), 6.99(d, 1H), 4.36(m, 2H O-CH2), 3.74(dd, 4H piperazine), 3.56(dd, 4H 
piperazine), 1.36(td, 3H CH3). 
ESI-MS M/Z for C16H18F3N5O 354.18 (M+H)
 + 
 
2.1.6.2. 3'-Isopropoxy-4-(5-trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro- 
2H-[1,2']bipyrazinyl {YAN-2 (19)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.87; yellow powder, 0.529g; yield = 99%. 
 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.41(s, 1H), 7.80(dd, 1H), 7.72(d, 1H pyrazine), 7.59(m, 
1H pyrazine), 6.99(d, 1H), 5.26(m, 1H O-CH), 3.74(dd, 4H piperazine), 3.54(dd, 4H piperazine), 
1.33(dd, 6H (CH3)2). 
 
YAN-3 (20): To a stirred solution of sodium (0.133 g, 5.818 mmol) in dry THF (10 ml), the 
desired alcohol phenol (0.136 g, 1.454 mmol) was added. The mixture was stirred at ambient 
temperature for 30 minutes. After that 2,3-dichoropyraizne derivative {(A7), 7} (0.5 g, 1.454 
mmol) was added and the mixture was heated to reflux for 18 hours under calcium chloride. 
Reaction completion was monitored by TLC (ethyl acetate: CHCl3; (50:50 v/v)). Upon reaction 
completion the solution was evaporated to dryness under vacuum and extracted against ethyl 
acetate and water, the combined organic extracts were pooled, dried over sodium sulfate, and 
concentrated. The residue was adsorbed onto Silica and purified by column chromatography 
(ethyl acetate /hexane) to give the desired product YAN-3 (20) in 89% yield. 
 
2.1.6.3. 3'-Phenoxy-4-(5-trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro- 
2H-[1,2']bipyrazinyl {YAN-3 (20)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf =0.65; colorless oil, 0.511g; yield = 87.6%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.32(s,1H), 8.18(dd,1H), 7.91(d,1H), 7.71(d,1H 
pyrazine),  7.03(m,2H phenol), 6.89(m,1H phenol), 6.63(m,3H phenol and pyrazine),  
3.65(m,4H), 3.38 (m,4H). 
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2.1.7. Synthesis of (2,3-diamino pyrazine) derivatives under acidic conditions 
To a solution of A7 (7) (0.5g, 1.454 mmol) in dioxane or tetrahydrofuran (20 ml), excess of HCl 
37% (approximately 1ml) and the corresponding aromatic amine (1.6 mmol) were added 
respectively. While being stirred, few drops of distilled water were added to aid salt solvation. 
The mixture was heated to reflux for 10-14 hour. Reaction completion was monitored by TLC 
(ethyl acetate: CHCl3; (50:50 v/v)). Upon reaction completion, if a precipitate formed the 
mixture was concentrated and carefully filtered out using suction filtration. If no or little 
precipitate formed, volatile components of the mixture were evaporated to dryness under 
vacuum, the residue was extracted against ethyl acetate (3 x 30 ml). pH adjustment was made to 
liberate the compound from its salt form. Organic extracts were then pooled, dried using sodium 
sulfate, and re evaporated to afford the desired product in 69-81 % yield. 
 
2.1.7.1.  N-[4-(5-Trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-
yl]-benzene-1,4-diamine {YAN-4 (21)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf =0.53; brown powder, 0.489g; yield = 81.01%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.73(m, 2H pyridine N-CH and NH), 7.99(d, 1H 
pyrazine), 7.90(m, 1H pyridine), 7.84(d, 1H pyrazine), 7.67(m, 2H benzene), 6.66(d, 1H 
pyridine), 6.28(m, 2H benzene), 4.52(s, 2H amine), 4.15(m, 6H piperazine), 3.97(m, 2H 
piperazine). 
 
2.1.7.2.  4-[4-(5-Trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-
ylamino]-benzoic acid {YAN-5 (22)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf =0.27; orange powder, 0.467g; yield = 72.3%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.41(s, 1H pyridine N-CH), 7.87(d, 3H benzene and 
pyridine), 7.10(m, 4H pyrazine and benzene), 6.75(d, 1H pyridine), 4.14(m, 4Hpiperazine), 
3.85(m, 4H piperazine). 
 
2.1.7.3. 4-[4-(5-Trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-3'-
ylamino]-phenol {YAN-6 (23)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf =0.34; dark brown powder, 0.422g; yield = 69.1%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 10.22(s,1H hydroxyl), 8.32(d, 1H pyridine N-CH), 
7.95(m, 1H pyridine),  7.13(dd, 2H pyrazine), 6.79(m, 6H), 6.08(s, 1H amine), 4.22 (s, 2H), 
3.86(dt, 3H), 3.51(d, 2H). 
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2.1.7.4.  Pyridin-2-yl-[4-(5-trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro-2H-
[1,2']bipyrazinyl-3'-yl]-amine {YAN-7 (24)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.62; white powder, 0.435g; yield = 74.5%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.41(s, 1H pyridine N-CH), 8.19(d, 2H pyridine N-CH 
amine), 7.90(m, 3H pyrazine), 7.03(m, 1Hpyridine), 6.81(m, 3Hpyridine), 5.40(s, 1H), 4.15(s, 
2H piperazine), 3.83(m, 4H piperazine), 3.49(d, 2H piperazine). 
 
2.1.8. Synthesis of symmetrical (2,3-diamino pyrazine) derivatives 
2.1.8.1.     N, N'-Di-pyridin-2-yl-pyrazine-2,3-diamine {YAN-8 (25)} 
 
To a solution of 2,3-dichloropyrazine (0.5 ml, 4.8 mmol) and 2-aminopyridine (0.99 g, 10 mmol)  
in dioxane (10 ml), excess HCl 37% (2 ml) was added. While being stirred, few drops of distilled 
water were added to aid salt solvation, and the reaction mixture was heated to reflux for 18 hour. 
Upon reaction completion a precipitate formed and the mixture was concentrated and carefully 
filtered out using suction filtration and washed to give the desired product. 
TLC (EA: CHCl3 (50:50; v/v)), Rf = salt; off-white powder, 1.161g; yield = 91.5%. 
1H-NMR300 MHz (DMSO-d6, δ ppm): 7.84 (m, 2H pyridine), 7.51 (m, 4H pyrazine and 
pyridine), 6.66 (d, 2H pyridine), 6.45 (d, 2H pyridine). 
 
2.1.8.2.    2,3-bis(4-(5-trifluromethyl)pyridine-2-yl)piperazine-1-yl)pyrazine {YAN-9 (26)} 
 
To a stirred solution of 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine (3.21 g, 10 mmol) and 
K2CO3 (1.46 g, 10 mmol) in DMSO (5 ml), 2,3-dichloropyrazine (0.5 ml, 4.8 mmol) in DMSO (5 
ml) was gradually added. The reaction mixture was refluxed at 100 °C for 10-12h. The 
completion of the reaction was indicated by TLC (CHCl3). Upon reaction completion the mixture 
was evaporated to dryness and the crude product was extracted by ethyl acetate (3 x 30 ml). The 
organic extracts were collected, dried over sodium sulfate, and concentrated. Finally 
recrystallization using ethanol was done to give the desired product. 
TLC (CHCl3), Rf = 0.69; brown oil, 2.296g; yield = 88.7%. 
 
1H-NMR300 MHz (DMSO-d6, δ ppm): 8.40(d, 2H), 8.07(s, 2H pyrazine), 7.80(d, 2H), 6.99(d, 
2H), 3.63(m, 8H piperazine), 3.44(m, 8H piperazine). 
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2.1.9.  Synthesis of YAN-5 (22) analogues via coupling reactions  
 
To a solution of YAN-5 (22) (0.5g, 1.12 mmol) in dioxane (10 ml), N-hydroxysuccinimide 
(NHS) (0.28 g, 2.47 mmol), dicyclohexyl carbodiimide (DCC) (0.5g, 2.47 mmol) and TEA (0.59 
g, 6.75 mmol) were added. The mixture was stirred at room temperature for 5 hours followed by 
the addition of the desired amine (ethanol amine or glycine methyl ester, 2 mmol). Reaction 
progress was monitored using TLC (ethyl acetate). If needed, the reaction was heated for 2-3 
hours to speed up the coupling process. Upon reaction completion the mixture was evaporated to 
dryness and dissolved in cold ethyl acetate to precipitate the DCU. Suction filtration and washing 
with cold ethyl acetate were used to remove the precipitate. Finally, the filtrate was evaporated to 
yield the product YAN-11 (28) in good yield (87%). 
In case of YAN-10 (27) further purification was needed, the crude was adsorbed to silica gel 
column chromatography and eluted using (ethyl acetate /DCM). The compound was retrieved 
with a yield of 64%. 
 
2.1.9.1.    {4-[4-(5-Trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro-2H [1,2']bipyrazinyl-3'-
ylamino]-benzoylamino}-acetic acid methyl ester {YAN-10 (27)} 
TLC (EA), Rf = 0.3; pale yellow powder, 1.142g; yield = 87%. 
 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.70(m, 1H N-CH pyridine), 8.01(d, 1H pyrazine), 
7.88(m, 2H pyrazine), 7.77(m, 2H benzene), 7.70(m, 2H benzene), 6.66(d, 1H), 4.15(m, 8H 
amide CH2, piperazine), 3.98(m, 2H piperazine), 3.65(s, 3H O-CH3). 
 
2.1.9.2. N-(2-Hydroxy-ethyl)-4-[4-(5-trifluoromethylpyridin-2-yl)-3,4,5,6-tetrahydro-2H-
[1,2']bipyrazinyl-3'-ylamino]-benzamide {YAN-11 (28)} 
TLC (EA), Rf = 0.27; off white powder, 0.624g; yield = 64%. 
 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.72(d, 1H N-CH pyridine), 8.67(t, 1H NH amide), 
8.0(d, 1H pyrazine), 7.88(m, 2H pyrazine), 7.74(m, 2H benzene), 7.70(m, 2H benzene), 6.66(d, 
1H), 4.15(m, 6H piperazine), 3.98(m, 2Hpiperazine), 3.55(m, 2H NH-CH2), 3.38(m, 2H OH-
CH2). 
 
2.1.10.  Bromination of pyrazine derivative A1 (1) 
To a stirred solution of {(A-1), 1} (1.5g, 8.6mmol) in ACN (8 ml), N-bromosuccinimde (NBS) 
(1.69 g, 9.46 mmol) was gradually added. The reaction mixture was stirred at room temperature 
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overnight. The completion of the reaction was monitored by TLC with a suitable elution system 
(ethyl acetate: CHCl3; (50:50 v/v)). Upon reaction completion the precipitate was collected using 
suction filtration, washed with cold water and dried to provide the desired pure product. 
 
 
2.1.10.1.       2-(5-Bromo-3-chloropyrazin-2-ylamino)-ethanol {YAN-12 (29)} 
TLC (EA: CHCl3 (50:50; v/v)), Rf = 0.52; dark yellow powder, 2.05g; yield = 94.3%. 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 8.16(d, 1H pyrazine position 6), 7.08(s, 1H amine), 
4.69(s, 1H hydroxyl), 3.51(m, 2H), 3.39(d, 2H).   
                                                                                                                         
2.1.11. Synthesis of 2-amino-5-alkoxy pyrazine derivatives 
To a stirred solution of sodium (0.133 g, 5.818 mmol) in the desired alcohol (10 ml), YAN-12 
(29) (0.3g, 1.18mmol) was added and the mixture was heated to reflux for 19 h under calcium 
chloride. Reaction completion was monitored by TLC (ethyl acetate: CH2Cl2; (50:50 v/v)). Upon 
reaction completion volatiles were evaporated to dryness under vacuum and the crude was 
extracted against ethyl acetate and water (3 x 30 ml). The combined organic extracts were 
pooled, dried over sodium sulfate, and concentrated. Recrystallization using ether was performed 
to afford YAN-13 (30) and YAN-14 (31) in yields 98.2 % and 96.4%. 
 
2.1.11.1.  2-((3-chloro-5-ethoxypyrazin-2-yl)amino)ethanol {YAN-13 (30)} 
TLC (EA: CH2Cl2 (50:50; v: v)), Rf =0.76; white powder, 0.253g; yield = 98.2%. 
 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 7.69(s, 1H pyrazine), 4.75(m, 1H hydroxyl), 4.30(m, 2H 
O-CH2), 3.64 (m, 4H CH2-CH2), 1.35(t, 3H CH3) 
 
 
 
 
2.1.11.2.  2-((3-chloro-5-isopropxypyrazin-2-yl)amino)ethanol {YAN-14 (31)} 
TLC (EA: CH2Cl2 (50:50; v: v)), Rf =0.830; white powder, 0.266g; yield = 96.4%. 
 
1
H-NMR300 MHz (DMSO-d6, δ ppm): 7.69(s, 1H pyrazine), 4.82(m, 1H O-CH), 4.75(m, 1H 
hydroxyl), 3.63 (m, 4H CH2-CH2), 1.27(m, 6H (CH3)2) 
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2.1.11.3. N-(3-((6-chloro-5-((2-hydroxyethyl)amino)pyrazin-2-yl)oxy)phenyl)acetamide 
{YAN-15 (32)} 
To a stirred solution of potassium carbonate (0.19 g, 1.41 mmol) in dioxane (10 ml), 
acetaminophen (0.179 g, 1.18mmol) was added and the mixture was stirred at room temperature 
for 15 minutes. Afterwards, YAN-12 (29) (0.3g, 1.18mmol) was added and the mixture was 
heated to reflux overnight. Reaction completion was monitored by TLC (ethyl acetate: CHCl3; 
(50:50 v/v)). Upon reaction completion volatiles were evaporated to dryness and extracted 
against ethyl acetate (3 x 30 ml). The combined organic extracts were pooled, dried over sodium 
sulfate, and concentrated. The residue was purified by column chromatography (ethyl acetate 
/hexane) to give YAN-15 (32) in good yield. 
 
TLC (EA: CHCl3 (50:50; v/v)), Rf =0.22; white powder, 0.339g; yield = 94%. 
 
1
H-NMR300 MHz (DMSO, δ ppm): 10.05(s, 1H amide), 7.75 (s, 1H pyrazine), 7.62(d, 1H), 7.14 
(d, 1H), 3.54 (d, 2H benzene ring), 3.37 (d, 2H benzene ring), 1.99(s, 3H CH3) .Melting point: 
143-145 C. 
 
 
A summary of the mono and disubstituted synthesized compounds is shown in table 2.3 below. 
 
 
Table 2.3: List of synthesized compounds showing their chemical and structural formals 
 
N
N R2
R1
R3
1
2
3
4
5
6
 
General formula 
 
Com 
# 
Com. 
code 
R1 R2 R3 
Chemical 
formula 
1 A1* 
 
N
H
OH
 
Cl H C6H8ClN3O 
2 A2* 
 
N
OH
 
Cl H C7H10ClN3O 
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3 A3 
 
O
OH
N
H
 
Cl H C6H6ClN3O2 
4 A4 
 
O
O
N
H
 
Cl H C7H8ClN3O2 
5 A5 
 
N
H  
Cl H C8H12ClN3 
6 A6 
 
N N
OH
 
Cl H C10H15ClN4O 
7 A7 
 
N N
N
F
F
F  
Cl H C14H13ClF3N5 
8 A8 
N N
N
F
F
F
 
Cl H C14H13ClF3N5 
9 A9 
 
N N
N
N  
Cl H C12H13ClN6 
10 A10 
 
N N N
 
Cl H C13H14ClN5 
11 A11 
 
NN
 
Cl H C14H21ClN4 
12 A12 
 
N
N
N
N
NH2
 
Cl H C9H6ClN7 
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13 A13 
N
H
NH2
 
 
Cl 
 
 
H 
C10H9ClN4 
 
14 A14 
N
H
N
 
Cl H 
C9H7ClN4 
 
15 A15 
O
OH
N
H  
Cl H 
C11H8ClN3O2 
 
16 A16 
N
H
OH
 
Cl H 
C10H8ClN3O 
 
17 A17 
O
H
N
HO  
Cl H 
C12H10ClN3O2 
 
18 YAN-1 N N
N
F
F
F  
O
 H 
C16H18F3N5O 
 
19 YAN-2 N N
N
F
F
F  O  
H 
C17H20F3N5O 
 
20 YAN-3 N N
N
F
F
F  
O
 
H 
C20H18F3N5O 
 
21 YAN-4 N N
N
F
F
F  NH
NH2
 
H 
C20H20F3N7 
 
22 YAN-5 N N
N
F
F
F  
O
OH
N
H  
H 
C21H19F3N6O2 
 
23 YAN-6 N N
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30 
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C8H12ClN3O2 
31 
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O  
C9H14ClN3O2 
 
32 
YAN-
15 
N
H
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Cl 
 
OHN
O
 
C14H15ClN4O3 
 
 
A1* CAS number: 84066-20-6 
A2* CAS number: 1353960-18-5 
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2.2.  Initial in vitro biological activity  
Some of the synthesized pure and well characterized compounds were initially assessed for 
their in vitro biological activity at professor‟s Bjørn Tore Gjertsen lab, department of clinical 
science. University of Bergen- NORWAY. 
 
Cell line 
Acute monocytic leukemia (Molm-13) cell line was utilized in the in vitro assessment. They 
were obtained from a 20 years old acute myeloid leukemia (AML) patient. Part of the cell line 
had been stably transfected by sh-RNA while the other part was transfected by sh-p53 RNA.  
 
Medium 
RPMI1640 medium, originally developed by Moore and his coworkers at Roswell Park 
Memorial Institute in 1966, was used to cultivate the cell line that was used for testing our 
compounds. RPMI has successfully been used for the cultivation of normal human and 
neoplastic leukocytes. It has been widely used in fusion protocols and in the growth of hyprid 
cells.  It was formulated to support lymphoblastoid cells in suspension culture. 
 
In vitro assay 
WST-1 assay was used to determine cells viability, the assay is based on the cleavage of 
tetrazolium salt into a colored soluble formazan dye by a complex cellular mechanism that 
involves mitochondrial dehydrogenase enzymes. As the bio-reduction process is largely 
dependent on the glycolytic production of NADPH in viable cells, the amount of formazan 
dye formed directly correlates to the number of metabolically active cells in the given culture. 
Cells grown in the culture plate are incubated with the WST-1 reagent for 0.5 - 4 hours. After- 
wards, the formazan dye formed is quantitated with a scanning multi-well spectrophotometer 
(ELISA reader). The measured absorbance directly correlates to the number of viable cells. 
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2.3. Computational chemistry of the synthesized compounds 
2.3.1. Computer-aided prediction of biological activity spectra of the synthesized 
compounds 
Biological activity is defined as the inherent capacity of a substance to alter any chemical or 
physiological functions of a biological entity. A biologically active compound may exert its 
action via various mechanisms; the specificity of action is always relative and is defined by a 
number of peculiarities including but not limited to object, dose, and route. On the other hand, 
the biological potential of compound includes all activities, which can be discovered under some 
specific experimental conditions, and it is called the biological activity spectrum. The spectrum 
of compound can be predicted on the basis of structure-activity relationships found by the 
analysis of the known data from the training set.
[90]
 PASS (Prediction of Activity Spectra for 
Substances) is one such program that predicts the possibility of a drug to be active against a 
target based on the physico- chemical methods using various algorithms and comparisons 
[91] 
. 
This Computer program was the product of ideas originated more than 25 years ago within the 
framework of the National Registration System of New Chemical Compounds organized in the 
USSR in 1972
[92]
.  First the idea was introduced by V.Avidon who suggested that many kinds of 
biological activity could be predicted on the basis of structural formula of chemical 
compound
[93]
. Meanwhile, Similar approach was under development by V.Golender and 
A.Rozenblit 
[94]
. 
 
PASS concurrently predicts several hundreds of biological activities (pharmacological main and 
side effects, mechanisms of action, mutagenicity, carcinogenicity, teratogenicity and 
embryotoxicity). The biological activity spectrum of a compound shows all compound's actiones 
despite the difference in essential conditions of its experimental determination process. If the 
difference in (species, sex, age, dose, route, etc) is ignored, the biological activity can be only 
qualitatively identified. As a result, "the biological activity spectrum" is defined as the "intrinsic" 
property of a compound depending only on its structure and physico-chemical characteristics. 
Prediction of this spectrum by PASS is based on SAR analysis of the training set containing 
more than 35,000 compounds which have more than 500 kinds of biological activity
[95]
. Thus, 
PASS once trained is able to predict simultaneously all biological activities which are included in 
the training set (library). To provide the best quality of prediction new information about 
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biologically active compounds is collected permanently from papers and electronic sources, 
evaluated and then regularly added to the training set
[95]
. 
 
PASS uses CSV, SD or MOL-files as input, data Analysis using this program is based on a 
number of chemical descriptors that are called multilevel neighborhoods of atoms (MNA), the 
descriptors are automatically generated on the basis of MOL-file of the assisted molecule. The 
list of MNA descriptors currently consists of more than 35700 different items. Frequently, new 
descriptors are added to this list in order to refresh it. Those descriptors are effectively applied in 
SAR, QSAR and similarity analysis. Finally the output results of prediction can be obtained as 
TXT or SD-files. Since the prediction of biological activity spectra for 1,000 compounds in usual 
PC takes about 1 minute, PASS can be effectively applied to predict biological potential of 
separate compounds and to analyze large chemical databases.  
 
PASS algorithm was selected by theoretical and empirical comparison of many different 
mathematical methods to provide high accuracy of prediction and robustness of calculated 
estimated data. The mean accuracy of biological activity prediction with PASS is 70±80% both 
in prediction for independent test and leave-one-out cross validation. However, the reliability of 
predictions relates to the researcher's purpose. The ultimate decision on how many and which 
structures should be selected for testing depends on the estimated probabilities for a compound to 
be active (Pa) and inactive (Pi), experimental facilities and the researcher's aspiration concerning 
the extent of innovation in the result sets of about 5000 compounds diverse in both structure and 
activity
[96, 97]
. 
 
Biological Activity Spectra Prediction 
Biological activity of the synthesized compounds was assisted using PASS. The structure of the 
compounds was first drawn using ISIS draw version 2.4. Then all the calculations were 
performed using PASS 2012 demo version. Description of current version of computer system  
PASS and feasibility for its free testing are available via Internet on: 
http://www.genexplain.com/pass 
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2.3.2. Lipinski's rule of five: computational approach to predict drug-likeness of the 
synthesized compounds  
Several computational approaches were used to estimate solubility and permeability of chemical 
structures in discovery and development stages. Lipinski's rule of five  or simply the Rule of 
five (RO5) evaluate drug likeness or determine if the chemical entity  has properties that would 
make it a likely orally active compound, in addition it describes the required molecular features 
that are  considered important for a drug's pharmacokinetics “ADME” (absorption, distribution, 
metabolism, execration) in vivo. Christopher A. Lipinski lunched this rule in 1997, based on the 
observation that most orally administered drugs are relatively small and moderately lipophilic in 
nature.  
 
The rule of 5‟ states that good absorption or permeation is more likely when there are less than 5 
H-bond donors, 10 H-bond acceptors, the molecular weight (MWT) is smaller than 500 Dalton‟s 
and the calculated octanol-water partition coefficient (Log P) is not greater than 5. Afterward, 
and In an attempt to improve the predictions of drug-likeness, the rules have spawned many 
extensions, indicating that the chemical entity should meet the following criteria : Partition 
coefficient (log P) in −0.4 to +5.6 range, Molar refractivity  ranges from 40 to 130, Molecular 
weight between 180 to 500, total Number of atoms from 20 to 70, and Polar surface area not 
greater than 140 Ǻ2. 
 
Drug-likeness of the synthesized compounds was assisted using Chemicalize, A public web 
resource which gives structure-based predictions. The structure and IUPAC name of the 
compounds was generated using ChemDraw ultra. Then all the calculations were performed 
using Chemicalize. Description of the public resource of Chemicalize and feasibility for its free 
testing are available via Internet on: http://cds.rsc.org/chemicalize.asp. 
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2.3.3. Docking of the synthesized compounds using SwissDock, a protein-small 
molecule docking web service based on EADock DSS. 
Currently, it is well known that most of the vitality processes in life involve complex interactions 
between two molecules at least. Moreover, the prediction of binding modes occurring between a 
small molecule and a target protein of biological interest is crucial for drug development and can 
be performed by the aid off so-called docking software. 
 
In our study, docking calculations were conducted with SwissDock, a protein small molecule 
docking web service based on EADock DSS. SwissDock algorithm consists of many steps; first 
the structure of the target protein, as well as that of the ligand must be specified.  In our study the 
crystal structure of human cyclin-dependent kinase was obtained from the PDB with the 
accession code 1HCL. Ligand 3D structure was obtained by the conversion of ChemDraw 
(Cdxml) file for each compound into (MOL2) file using Open Babel GUI software version 2.4.1. 
 
Once the target and ligand have been designed the prediction parameters were selected and the 
docking assay was submitted. All calculations were performed on the server side and the output 
results were sent to user by email. Many binding modes were generated in the vicinity of all 
target cavities (blind docking), their CHARMM energies were estimated, the binding modes with 
the most favorable energies were evaluated and clustered, and the most favorable clusters can be 
visualized online and downloaded on a personal computer. 
 
Finally the interpretation of docking results was greatly facilitated by the visualization of 
docking predictions in the UCSF Chimera1.11.2 molecular viewer, which can be launched 
directly from the web browser. 
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3. Results and discussion 
3.1. Chemical synthesis of compounds 
Pyrazine, one of the naturally occurring diazines is an aromatic heterocyclic ring with two 
nitrogen atoms located in the 1 and 4 positions of the heterocycle. Pyrazine bear multiple 
functionalities that may be transformed into diverse derivatives using a sequence of chemical 
reactions. Pyrazine is considered less reactive compared to other related diazines, this is mainly 
due to the symmetrical Para position of the electron-attracting nitrogen atoms which makes 
pyrazine a weaker base (pKb = 13.49) than its isomeric analogous pyrimidine (pKb = 12.77), or 
pyridazine (pKb = 10.76) and hence decreases its reactivity. 
 
Since pyrazine is considered a 6π-electron-deficient aromatic system -Nitrogen in pyrazine 
withdraws electrons from the ring rather than donates to it - it could undergo sequential aromatic 
substitution reaction (SNAr). In SNAr a nucleophile attacks an electron deficient aromatic ring 
with a good leaving group. A resonance stabilized carboanion is formed, and the leaving group 
departs as the aromatic ring π system is reestablished. Taking a deep look at pyrazine scaffold it 
can be seen that the electron deficiencies are at 2, 3, 5 and 6 positions of the ring. Therefore, 
nucleophilic reagents could attack these positions. Still yet, halogenated forms of pyrazine at the 
previously mentioned positions are needed to make the substitution easier. The presence of 
“halogen” another electron withdrawing group that normally deactivates the ring in electrophilic 
aromatic susbstitutions makes pyrazine more electrons deficient and a good candidate for SNAr.  
Different commercially available chloro and poly-chloropyrazines where used to create a wide 
panel of pyrazine based derivatives. Even so, few studies were concerned in developing 2,3-
disubstituted pyrazine derivatives so it was the subject of our research.  
 
In the current study commercially available 2,3-dichloropyrazine was used as the core scaffold, 
and the derivatives were synthesized by sequential aromatic substitution reaction (SNAr) under 
different conditions depending on the nucleuphile itself and the order of substitution. The overall 
Strategy for synthesis of the desired disubstitued pyrazine derivatives is depicted in Scheme 3.1. 
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Scheme 3.1: Sequential substitution of 2,3-dichloropyrazine by various nucleophiles. Typical 
method for preparation of monosubstituted and disubstituted pyrazines. Nuc: nucleophile, NBS: 
N-bromosuccinimide used for C-H activation. 
 
As indicated in scheme 3.1 different groups of compounds have been synthesized in the course 
of the current study. The final products classified as 2,3-disubstituted pyrazines were synthesized 
in a way to mimic CDK inhibitors mainly pyrollopyrazine. All the functional groups were 
selected to accommodate the CDK binding site. 
 
3.1.1. Synthesis of mono-amino substituted pyrazines (1-16) 
First we aimed at exploring the possibility of introducing different nucleophilic moieties 
(aliphatic and aromatic amines) as first substituent on the pyrazine core. The reactions were done 
using reported procedures according to the type of nucleophile used.  
 
3.1.1.1. Synthesis of 2-amino-3-chloropyrazine derivatives under basic conditions (1-12) 
The planned compounds were prepared starting from commercially available 2,3-
dichloropyrazine which was reacted with the corresponding aliphatic amine under basic 
conditions using TEA or DIPEA as base and dioxane or tetrahydrofuran as solvent.  The reaction 
proceeds via aromatic nucleophilic substitution SNAr. The amine attacks the electron deficient 
pyrazine aromatic ring. A resonance stabilized carboanion is formed. Resonance delocalizes the 
negative charge over the entire ring causing the “chlorine” leaving group to leave the ring. The 
nucleophilic displacement of chlorine by aliphatic amines proceeded under elevated 
temperatures. After reaction completion, volatiles were evaporated under vacuum. The residue 
was extracted against ethyl acetate and water and the organic layer was then pooled, dried using 
55 
 
sodium sulfate and condensed. If needed the crude product was purified using recrystallization or 
silica gel column chromatography using (CHCl3: hexane) as eluent to give the 2-amino-3-
chloropyrazine derivatives in good yields ranging from 77-91%. 
 
Different aliphatic acyclic amines were used to displace the chlorine group on position 2 of the 
pyrazine core including ethanol amine, 2-methylethanolamine, glycine, glycine methyl ester, and 
n-butylamine as shown in scheme 3.2. 
HN
OH
N
OH
O
OH
N
H
O
O
N
H
N
H
N
N Cl
Cl
NH2-R
(a)
N
N Cl
R
R=
A2 (2)
88.9%
A3 (3)
82.6%
A4 (4)
87.4%
A1 (1)
91.8%
A5 (5)
77.2%
 
Scheme 3.2: Representative procedure for the synthesis of (2-amino-3-chloropyrazine) 
derivatives using acyclic amines under basic conditions. (a) Dioxane or THF, TEA or DIPEA, 
stirring at reflux, R= aliphatic linear amine. 
  
Furthermore, wide range of pyridine heterocyclic amines were introduced to the pyrazine core 
including piperazine and pyridine derivatives such as 2-piperazin-1-yl-ethanol, 1-(5-
trifluoromethylpyridin-2-yl)-piperazine, 1-(3-trifluoromethylpyridin-2-yl)-piperazine, 1-pyridin-
4-yl-piperazine, 2-piperazin-1-yl-pyrimidine, [1,4'] bipiperidinyl-piperazine as shown in scheme 
3.3. Pyridine containing derivatives are considered among the important aliphatic heterocyclic 
moieties, they are found in various compound classes exhibiting wide range of pharmacological 
activities that‟s mainly the reason why they were chosen. 
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Scheme 3.3: Representative procedure for the synthesis of (2-amino-3-chloropyrazine) 
derivatives using cyclic amines under basic conditions. (a) Dioxane or THF, TEA or DIPEA, 
stirring at reflux, R= aliphatic cyclic amines. 
 
3.1.1.2. Synthesis of 2-amino-3-chloropyrazine derivatives under acidic conditions 
The compounds were prepared starting from commercially available 2,3-dichloropyrazine which 
was reacted with the corresponding aromatic amine under acidic conditions using HCl (37%)  
and dioxane or tetrahydrofuran as solvent as shown in scheme 3.4. It is unclear which 
mechanistic pathway this reaction proceeds through. However, the presence of HCl makes it 
difficult to consider a nucleophilic aromatic substitution mechanism. Indicatively, amines are 
basic so they tend to neutralize the added acid forming a salt product; few drops of distilled water 
were added to aid salt solvation. This whole process may increase the solubility of the amine therapy 
increase the rate of the reaction. The mixture was heated to reflux for 2-8 hours which is a short time 
in comparison to basic conditions. Upon reaction completion - in most cases- a precipitate was 
formed and carefully filtered out using suction filtration. However, if no or little precipitate formed 
the volatiles were evaporated under vacuum, the residue was extracted against ethyl acetate and 
water, pH adjustment was made to liberate the compound from its salt form, the organic layer was 
then pooled, dried using sodium sulfate and re evaporated to afford the desired 2-amino-3-
chloropyrazine derivative in 84-93 % yield. 
57 
 
N
N Cl
Cl
NH2-R
(a)
N
N Cl
R
R=
A14 (14)
84%
A15 (15)
86.9%
A16 (16)
88%
A13 (13)
93.4%
N
H
NH2
N
H
N
O
OH
N
H
N
H
OH
 
Scheme 3.4: Representative procedure for the synthesis of (2-amino,3-chloropyrazine) 
derivatives using aromatic amines under acidic conditions. (a) Dioxane or THF, HCl, stirring at 
reflux, R= aromatic amines. 
 
From our experimental trials we noticed that aromatic amines tend to slowly react with 2,3-
dichloropyrazine under basic conditions, so new alternative approach was needed to speed up the 
reaction. Surprisingly, the use of acidic conditions along with aromatic amines increased the rate and 
the yields of the reactions in comparison with basic conditions using the same amount of reactants. 
 
3.1.2. Synthesis of mono-alkoxy substituted pyrazine derivatives (17) 
2,3-Dichlorpyrazine was reacted with acetaminophen in dioxane under basic condition using 
K2CO3 as shown in scheme 3.5.  The mixture was heated to reflux for 7 h, the completion of the 
reaction was monitored by TLC with a suitable elution system of (ethyl acetate: CHCl3; (50:50 
v/v)). Upon reaction completion the solution was evaporated under vacuum and extracted against 
ethyl acetate and water, the combined organic extracts were pooled, dried over sodium sulfate 
and concentrated to afford A17 (17) as white powder with 95% yield. 
 
(a)
ClN
N Cl
O
H
N
HO
N
N Cl
O
H
N
O
A17 (17)
95.3%
 
Scheme 3.5: Synthesis of (2-alkoxy-3-chloropyrazine) derivative A17 (17). (a) Dioxane, K2CO3, reflux. 
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Acetaminophen itself is not a good nucleophile; therefore, a base must be added to deprotonate 
acetaminophen creating a stronger nucleophile (Scheme 3.6). Phenolic hydroxyl group shows a 
pKa range of 16.47-15.28 (in DMSO) while N-acetyl-amino group shows a pKa of 
approximately 25 (in DMSO), this information indicates that phenol is more acidic than N-
acetyl-amino group hence it can be deprotonated using mild bases like K2CO3. The conjugate 
base of phenol is resonance stabilized in a way that allows this type of acid-base reaction to 
occur, and the negatively charged phenoxide anion become a strong nucleophile and attacks 2,3-
dichloropyrazine on carbon 2.   
 
O
N
H
OH K2CO3
Dioxane
O NH
O
O NH
O
O NH
O
O NH
O O
HN
O
 
Scheme 3.6: Deprotonation and resonance stabilization of the phenolic hydroxyl group in 
acetaminophen using potassium carbonate. 
  
3.1.3. Synthesis of 2-amino-3-alkoxypyrazine derivatives (18-20) 
To prepare the planned derivatives, the intermediate A7 (7) was reacted with the desired 
protonated aliphatic or aromatic alcohol as shown in scheme 3.7. Since aliphatic alcohols have 
higher pKa values than phenols they require stronger bases to deprotonate them. Hence, Sodium 
metal a stronger base than K2CO3 was used for these reactions. Sodium metal converts the 
alcohol to alkoxide. Hydrogen gas liberated during the reaction that‟s why it should be done with 
great caution, under calcium chloride, and using dry glassware.  
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During the synthesis of YAN-1 (18) or YAN-2 (19) the alcohol itself (ethanol or isopropanol 
respectively) was used as both solvent and nucleophile, this means that the solvent was the 
conjugate acid of the alkoxide. Sufficient volume of the alcohol was first stirred with sodium at 
ambient temperature. A7 (7) was added and the mixture was heated to reflux for 12 hours (for 
both 18, 19). Upon reaction completion volatiles were evaporated. The residue was extracted 
using ethyl acetate. Organic fractions were dried using sodium sulfate, concentrated, and washed 
with ether and air dried to afford YAN-1 (18) and YAN-2 (19) in high yields of 97% and 99%, 
respectively. 
 
Regarding YAN-3 (20) phenol was added to a previously stirred solution of sodium in dry 
tetrahydrofuran. The mixture was stirred at ambient temperature for additional 30 minutes. A7 
(7) was then added and the mixture was heated to reflux for 18 hours (in total). Upon reaction 
completion volatiles were evaporated. Further purification using column chromatography (ethyl 
acetate: dichloromethane) was needed to produce (20) in 87.6% yield. 
  
We noticed that introducing alcohol directly to 2,3-dichloropyrazine was much easier as seen in 
the preparation of A17 (17), took less time, and needed milder basic condition in comparison 
with introducing alcohol to 2-amino-3-chloropyrazine derivatives. It is believed that the 
successive introduction of an electron donating substituent at position 2 decreased the rate of 
nucleophilic substitution and decreased the tendency of chlorine at position 3 to act as leaving 
group.  
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Scheme 3.7: Synthesis of 2-amino-3-alkoxypyrazine derivatives using A7 (7) and different 
aliphatic or aromatic alcohols, (a) sodium, reflux 12h under calcium chloride for YAN-1 (18), 
and YAN-2 (19). (a) Sodium, dry THF, reflux 18h under calcium chloride for YAN-3 (20). 
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3.1.4. Synthesis of di-amino substituted pyrazines 
3.1.4.1. Synthesis of asymmetrical 2,3-diaminopyrazine derivatives (21-24) 
To prepare the planned 2,3-diamino pyrazine, A7 (7) was reacted with the corresponding 
aromatic amine under acidic conditions using HCl (37%) and dioxane or tetrahydrofuran as 
solvent. It is unclear which mechanistic pathway this reaction proceeds through. However, the 
presence of HCl makes it difficult to consider a nucleophilic aromatic substitution mechanism. 
Indicatively, amines tend to neutralize the added acid forming a salt product; few drops of 
distilled water were added to aid salt solvation. The mixture was heated to reflux for 10-14 hour. 
Upon reaction completion in case of (21) and (22) a precipitate formed and carefully filtered out 
using suction filtration. In case of (23) and (24) volatiles were evaporated under vacuum, the residue 
was extracted against ethyl acetate and water. pH adjustment was made to liberate the compound 
from its salt form, the organic extracts were pooled, dried using sodium sulfate and re evaporated. In 
case of (23) further purification using column chromatography was performed. 
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Scheme 3.8: Synthesis of 2,3-diaminopyrazine derivatives using A7 (7) and different aromatic amines, 
(a) HCl, Dioxane, reflux.  
 
 
The introduction of the first amine - an electron donating group - at position 2 of pyrazine will 
exert a resonance donating effect and decrease the rate of nucleophilic substitution therapy 
inducing a significant deactivation toward the second amination. This deactivation may also rise 
from the steric bulk introduced by the substituent at position 2 and the decreased tendency of the 
chlorine atom at position 3 of pyrazine core to act as leaving group. Hence, elevated 
temperatures, higher concentration of nucleophiles and prolonged reaction time were needed.  
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3.1.4.2. Synthesis of symmetrical 2,3-diaminopyrazine derivatives (25,26) 
YAN-8 (25) was prepared starting from commercially available 2,3-dichloropyrazine which was 
reacted with 2.1 equivalents of  2-aminopyridine under acidic conditions using 37% HCl and 
dioxane as shown in scheme 3.9. While being stirred, few drops of distilled water were added to aid 
salt solvation and the mixture was heated to reflux for 18 hour. After reaction completion a 
precipitate formed and the mixture was concentrated and carefully filtered out and washed using 
suction filtration to give the desired product as off white powder with a yield of 74.5%. 
 
YAN-9 (26)
88.7%
YAN-8 (25)
74.5%
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Scheme 3.9: Synthesis of 2,3-diaminopyrazine symmetrical derivatives (YAN-8 (25), YAN-9 
(26)) using 2,3-dichloropyrazine and different amines, (a) HCl, Dioxane and DMF, reflux (b) 
K2CO3, DMSO, reflux. 
 
YAN-9 (26) was prepared starting from commercially available 2,3-dichloropyrazine which was 
reacted with 2.1 equivalents of 1-(5-trifluoromethylpyridin-2-yl)-piperazine under basic 
conditions using K2CO3 as base and DMSO as solvent as shown in scheme 3.9. After reaction 
completion the mixture was evaporated, cold water (ice) was added and then the mixture was 
extracted with chloroform multiple times. Organic extracts were pooled, dried using sodium 
sulfate, and concentrated to give the desired product as brown oil with a yield of 88.7%. 
 
We have noticed that the synthesis of symmetrical 2,3-diaminopyrazine derivatives require 
special reaction conditions, including longer reaction time, higher concentration of reactants, 
stronger acid/base. Moreover, aprotic solvents such as DMSO and DMF were used in SNAr 
because they could increase the solubility of the reactants and thereby increase the kinetic of 
reaction.    
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3.1.5. Extending the carboxylic acid terminus of YAN-5 (22) via amide bond formation  
The reaction of carboxylic acid with amine in presence of DCC and NHS coupling system is 
frequently used in practice for amide bond formation. First DCC (dicyclohexyl-carbodiimide) 
reacts with the carboxylic acid terminus of the compound creating an o-acylisourea intermediate 
which is considered a good leaving group. Afterwards, N-hydroxysuccinimide attacks the 
intermediate forming 1,3-dicyclohexyl-isourea which is directly converted to the side product 
1,3-dicyclohexyl-urea (DCU), the new intermediate is then subjected to the desired amine which 
results in amide bond formation as shown in scheme 3.10.  
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Scheme 3.10: Detailed mechanism showing the coupling of the carboxylic acid terminus with 
different amines, using DCC, NHS coupling system. 
 
As shown in scheme 3.11. YAN-5 (22) was added to a solution of DCC and NHS in dioxane and 
TEA, the mixture was stirred at room temperature for 5 h. The intended amines were dissolved in 
small amount of dioxane and added to the activated YAN-5 (22) solution. While being stirred, the 
reaction was left at room temperature overnight. Upon reaction completion the crude mixture was 
evaporated and re-dissolved in cold ethyl acetate. Insoluble DCU was removed by filtration and 
washed with cold ethyl acetate. The filtrate was condensed to give YAN-10 (27) in 87% yield. 
Regarding YAN-11 (28) further purification using column chromatography was needed to 
remove the remaining by-products; the compound was recovered with a yield of 64%. 
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Scheme 3.11: Synthesis of YAN-10 (27) and YAN-11(28) by extending the carboxylic acid terminus of 
YAN-5 (22) via amide bond formation using different amines, (a) DCC, NHS, Dioxane, TEA, room 
temperature overnight 
 
 
3.1.6. Bromination of pyrazine derivative A1 (1)   
A1 (1) was subjected to radical reaction conditions to explore the possibility of pyrazine ring 
activation. NBS was used for brominaion; it produces a controlled amount of Br radicals which 
allows controlling the number of bromines added. First NBS was gradually added to a solution of 
A1 (1) in acetonitrile at room temperature. The initiations step started with a heterolytic cleavage 
of the N-Br bond in NBS. Afterwards, NBS nitrogen abstracted a proton from HBr, and a 
bromide ion attacked the protonated NBS bromine forming Br2. Finally, pyrazine radical 
abstracted a bromine radical from Br2 to form the desired product. The detailed activation 
mechanism is described in scheme 3.12. 
 
The reaction of bromine atom with pyrazine is considered endothermic (energy of activation is 
high and the transition state is closer in energy to products than reactants) so no heating was 
needed and the reaction rate was very fast. A change in colour of the reaction and formation of 
precipitate was noticed with time. TLC showed almost a complete reaction after 2 hours, 
however, the reaction was left at room temperature overnight to ensure product formation. Upon 
reaction completion, the reaction mixture was cooled and YAN-12 (29) was collected by suction 
filtration as a solid orange-brown powder with 96.3% yield.  
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Bromination with NBS is highly selective 
because bromine forms a stable radical; the 
reactivity-stability principle states that with 
increased reactivity selectivity decreases. 
 
it was reported that bromination position is 
highly affected by the used solvent. Two 
separated studies disclosed that starting from 
2-aminopyrazine, if the bromination reaction 
was carried out using NBS in acetonitrile or 
dichloromethane the bromination will take 
place at carbon 5 of pyrazine (Para to the 
amine) and the resulted derivative will be 2-
amino-5-bromopyrazine
[98, 99]
. In contrast, B. 
Jiang et al. claimed that if the same reaction 
was done using DMSO the bromination will 
take place at both carbon 3 and 5 of the ring 
and the resulted derivative will be 2-amino-
3,5-dibromopyrazine
[100]
. 
 
 In our procedure acetonitrile was used as 
solvent therefore the bromination is likely 
takes place at position 5, para to the amine. 
Comparing 
1
H-NMR spectrum of A1 (1) and 
YAN-12 (29) revealed that the peak for the 
proton at position 5 of the pyrazine ring 
disappeared from (29) 
1
H-NMR spectrum, 
which confirms that bromination occurred at 
position 5. 
 
 
Scheme 3.12: Detailed mechanism showing C-H 
activation of A1 (1) using NBS. (a) NBS, 
acetonitrile, stirring at room temperature 
overnight. R= ethanolamine. 
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3.1.7. Synthesis of 2-amino-3-chloro-5-alkoxy pyrazine derivatives (30-32) 
The previously synthesized intermediate YAN-12 (29) was reacted with acetaminophen in 
dioxane under basic condition using K2CO3 as shown in scheme 3.13. Potassium carbonate 
deprotonates the phenolic hydroxyl group of acetaminophen as previously shown in Scheme 3.6. 
The conjugate base of phenol is resonance stabilized creating negatively charged phenoxide 
anion which as a strong nucleophile attacks YAN-12 (29) on carbon 5. The reaction was refluxed 
for 24 hours. Upon reaction completion YAN-15 (32) was isolated by column chromatography in 
94% yield.  
HO-R
(a),(b)
R=
YAN-13  (30)
98.2%
YAN-14 (31)
96.4%
YAN-15 (32)
94%
O
O
YAN-12 (29)
NHN
N ClBr
OH
NHN
N ClR
OH
O
HN
O
 
Scheme 3.13: Synthesis of 2-amino-3-chloro-5-alkoxy pyrazine derivatives (30) and (31), (a) 
Sodium, reflux, synthesis of (32): (b) K2CO3, Dioxane, reflux. 
 
During the synthesis of YAN-13 (30) and YAN-14 (31), YAN-12 (29) was reacted with 
deprotonated aliphatic alcohols, Sodium which is considered a stronger base than K2CO3 was 
used since aliphatic alcohols have high pKa values and therefore requires stronger bases to 
deprotonate them. Aliphatic alcohol itself (ethanol and isopropanol, respectively) was used as 
both solvent and nucleuphile. Sufficient volume of the alcohol was first stirred at ambient 
temperature with sodium to allow the alcohol to deprotonate. Hydrogen gas bubbles were noticed 
at this point indicating the deprotonation process. After the addition of (29), the mixture was 
heated to reflux for 19 hours (for both 30, 31). Upon reaction completion volatiles were 
evaporated, the crude was extracted with ethylacetate. The organic extracts were pooled, dried 
using sodium sulfate and concentrated. The product was washed with cold ether and air dried to 
afford YAN-13 (30) and YAN-14 (31), in high yields of 98.2 % and 96.4%, respectively.  
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YAN-12 (29) has two possible positions that could be attacked by the protonated alcohol. 
However, substitution at position 5 is preferred. Bromine is considered a better leaving group 
than chlorine because bromine is larger in size and is more polarizable, which lowers the overall 
energy of the reaction transition state.  
 
The presence of a substituent at the pyrazine ring will highly affect the rate and orientation of 
nucleophilic substitution; in fact it is a combination of resonance and inductive effects. The 
electron withdrawing substituents (Cl and Br) play an inductive effect on the other carbons 
which creates an electron deficient aromatic ring. Whereas the already existed amine -electron 
donating group- substituent at position 2 will increase the electron density on the ring through 
a resonance donating effect and decrease the rate of nucleophilic substitution. The resonance 
only allows electron density to be positioned at the ortho- and para- positions. Hence, these sites 
are more nucleophilic, and the system tends to react with electrophiles at these ortho-
 and para sites.  In addition, substitution at position 2 creates a steric bulk that favors the second 
substitution to take place at para position. 
 
3.2. Initial in vitro biological activity  
Some of the synthesized compounds were assessed for their in vitro biological activity 
against Acute Myeloid Leukemia (AML) cell lines. Aggressive AML is receptor tyrosine 
kinase mutant driven. As a result screening our compounds using AML cell line may reveal 
whether they work as tyrosine kinase inhibitors or not. The rationale behind choosing this cell 
line was that 2,3-disbustituted pyrazines may act as kinase inhibitors. P53 “the guardian of the 
genome” is a protein produced by the tumor suppressor p53 gene, this protein has the ability 
to detect any abnormality in cells growth or division and hence terminate the abnormal cells. 
Recent studies showed that p53 gene is mutated in more than 50% of human cancers
[101, 102]
. 
 
To evaluate whether our compounds act in a p53 dependent or independent manner, acute 
monocytic leukemia (Molm-13) cell lines were transfected with a short hairpin RNA (sh-
RNA). sh-RNA is RNA sequence engineered to suppress the expression of desired gene via 
RNA interference. Two forms of (Molm-13) cell lines were used; the first (Molm-13) 
transfected with sh-RNA empty vector and the second (Molm-13 sh-p53) transfected with sh-
p53 RNA. (Molm-13 sh-p53) are p53 knocked down. To develop an initial structure activity 
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relationship, A-7 (7) and three different analogues carrying ether functionality at position 3 of 
pyrazine were tested against the two forms of (Molm-13) cell lines and the viability of the 
cells was determined using WST-1 assay. The tested compounds have shown weak to 
moderate activity against Molm-13 cell line (empty vector) [IC50 = 39 to 63 µM] and Molm-
13 cell line (sh-p53) [IC50 = 18 to 63 µM]. A-7 (7) was relatively more potent than its 
analogues with IC50 of 18 and 39 µM against Molm-13 (sh-p53) and Molm-13 (empty vector), 
respectively. It could be concluded from IC50 values (table 3.1) that introducing an alkoxy 
substituent at position 3 result in a drop in the activity. Moreover, increasing the size of the 
alkoxy derivative at position 3 is directly proportional to decreasing the activity of the 
compound as shown in the case of YAN-1 (18), YAN-2 (19), and YAN-3 (20) which 
possesses ethanol, isopropanol and phenol derivatives, respectively. 
 
Table 3.1: Structure activity relationship and IC50 values of compounds (7, 18, 19, and 20). 
Com 
number 
Com 
code 
Compound structure 
IC50 (µM) 
Molm-13 
Empty vector 
IC50 (µM) 
Molm-13 
sh-p53 
 
7 
 
A7 
N N
N
N N F
F
F
Cl  
 
39 
 
18 
18 YAN-1 
N N
N
N N F
F
F
O
 
 
NA 
 
26 
19 YAN-2 
N N
N
N N
F
F
F
O
 
 
 
NA 
 
 
39 
 
 
20 
 
 
YAN-3 
N N
N
N N F
F
F
O
 
 
 
63 
 
 
63 
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YAN-1 (18) and YAN-2 (19) have shown a remarkable difference between the concentration 
response curve and the IC50 values derived from the two forms of Molm-13 cell lines (empty 
vector and sh-p35) suggesting that the compounds mechanism of action is p53 dependent 
(Figures 3.1, and 3.2).  
 
 
 
Figure 3.1: Concentration-response effect of A-7 (7), YAN-1 (18), YAN-2 (19), and YAN-3 
(20) on Molm-13 cancer cell lines. Cell viability was measured using WST-1 assay and the data 
expressed as the mean+-SD of two independent experiments. 
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Although p53 mutations have been detected in only about 5% of acute myeloid leukemia 
patients, they are considered an adverse factor for disease prognosis and response to 
chemotherapeutic agents. 
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            Molm-13 empty vector                              Molm-13 sh-p53 
Figure 3.2: Viability chart of molm-13 empty vector and molm-13 sh-p53 cells at different 
concentration (1, 3.16, 10, 31.6, and100 µM) of A-7 (7), YAN-1 (18), YAN-2 (19), and YAN-3 
(20). 
 
From this initial biological screening we concluded that 1-(5-trifluoromethylpyridin-2-yl)-
piperazine moiety is a good pharmacophore for the antineoplastic activity, so it was fixed at 
position 2 of the pyrazine ring and A-7 (7) was chosen as a lead compound, however we also 
concluded that different non-alkoxy substituents must be introduced at position 3 of the ring in 
order to increase the activity. 
 
The biological results were confirmed using “PASS” prediction of activity spectra software (see 
section 3.3 for details), the software predicted the same sequence of activity for A-7 (7), YAN-1 
(18), YAN-2 (19), and YAN-3 (20). Furthermore, and in aim to increase the chance of preparing 
new active compounds, different amine substituents were introduced to A-7 (7) (position 3 of 
pyrazine ring) computationally and their activity was predicted using PASS. Afterwards the 
active derivatives were synthesized. 
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3.3. Computational chemistry of synthesized compounds 
3.3.1.  Computer-aided prediction of biological activity spectra of the synthesized 
compounds: The PASS (prediction of activity spectra for substances) software was used to 
predict the pharmacological effect and the biochemical mechanism of the newly synthesized 
compounds according to their structural formula. Table 3.2 shows the results  
Table 3.2:  Computer-aided prediction of biological activity spectra (PASS) results of the synthesized compounds. 
 
Com. 
number 
Com. 
Code 
Structure   Expected activity Pa value 
7 A7 
N N
N
N N F
F
F
Cl  
Antineoplastic (non-
Hodgkin's lymphoma) 
0.604 
Autoimmune disorder 
treatments 
0.683 
12 A12 
N
N
N
N
H2N
N
N
Cl  
Antineoplastic 0.735 
Signal transduction 
pathway inhibitor 
0.444 
13 A13 
N
H
NH2
N
N
Cl  
Signal transduction 
pathway inhibitor 
0.927 
Antineoplastic ( solid 
tumors) 
0.824 
Preneoplastic 
conditions treatment 
0.478 
14 A14 
N
H
N
N
N
Cl  
Signal transduction 
pathway inhibitor 
0.962 
Antineoplastic ( solid 
tumors) 
0.862 
15 A15 
 
O
OH
N
H
N
N
Cl  
 
Signal transduction 
pathway inhibitor 
0.682 
Antineoplastic ( solid 
tumors) 
0.693 
Preneoplastic 
conditions treatment 
0.668 
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16 A16 
N
H
N
N
Cl
OH
 
Signal transduction 
pathway inhibitor 
0.853 
Antineoplastic ( solid 
tumors) 
0.753 
Preneoplastic 
conditions treatment 
0.645 
17 A17 O
H
N
O
N
N
Cl  
Antineoplastic ( solid 
tumors) 
0.543 
Signal transduction 
pathway inhibitor 
0.459 
18 YAN-1 
N N
N
N N F
F
F
O
 
Antineoplastic (non-
Hodgkin's lymphoma) 
0.611 
Anti-obesity 0.810 
19 YAN-2 
N N
N
N N
F
F
F
O
 
Antineoplastic (non-
Hodgkin's lymphoma) 
0.585 
Anti-obesity 0.794 
20 YAN-3 
N N
N
N N F
F
F
O
 
Antineoplastic (non-
Hodgkin's lymphoma) 
0.589 
Anti-obesity 0.925 
21 YAN-4 NH
H2N
N
N
N
N
N
F
F
F  
Antineoplastic (non-
Hodgkin's lymphoma) 
0.612 
Signal transduction 
pathway inhibitor 
0.734 
72 
 
22 YAN-5 
O
HO
NH
N
N
N
N
N
F
F
F  
Antineoplastic (non-
Hodgkin's lymphoma) 
0.582 
Signal transduction 
pathway inhibitor 
0.464 
23 YAN-6 NH
N
N
N
N
N
F
F
F
HO
 
Antineoplastic (non-
Hodgkin's lymphoma) 
0.600 
Signal transduction 
pathway inhibitor 
0.604 
24 YAN-7 NH
N N
N
N N
F
F
F
N
 
Antineoplastic (non-
Hodgkin's lymphoma) 
0.606 
Signal transduction 
pathway inhibitor 
0.803 
25 YAN-8 
NN
HNNH
N
N  
Signal transduction 
pathway inhibitor 
0.961 
Angiogenesis 
inhibitor 
0.825 
Antineoplastic 0.779 
Preneoplastic 
conditions treatment 
0.506 
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26 YAN-9 
N
N N
N N
F
F
F
N
N N
F
F
F  
Antineoplastic (non-
Hodgkin's lymphoma) 
0.667 
27 YAN-10 
O O
NH
O
NH
N
N
N
N
N
F
F
F
 
Antineoplastic (non-
Hodgkin's lymphoma) 
0.552 
Signal transduction 
pathway inhibitor 
0.337 
28 YAN-11 
O
NH
NH
N
N
N
N
N
F
F
F
HO  
Antineoplastic (non-
Hodgkin's lymphoma) 
0.607 
Signal transduction 
pathway inhibitor 
0.455 
29 YAN-12 NHN
N ClBr
OH
 
Signal transduction 
pathway inhibitor 
0.665 
30 YAN-13 
NHN
NO Cl
OH
 
Antineoplastic(solid 
tumors) 
0.344 
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31 YAN-14 
NHN
NO Cl
OH
 
Antineoplastic(solid 
tumors) 
0.381 
32 YAN-15 
O
H
N
O N
N NH
OH
Cl  
Antineoplastic(solid 
tumors) 
0.256 
 
Notes: 
Antineoplastics are agents that prevent or inhibit the maturation and proliferation of neoplasms in the 
body. 
Signal transduction pathway inhibitors are chemical structures that may prevent the ability of cancer 
cell to multiply quickly and invade other tissues 
Preneoplastic conditions treatment: treatment that is given to patients with genetically clinically, or 
morphologically defined conditions that are associated with high risk to develop cancer and increased 
incidence of malignant neoplasia with time.  
Non-Hodgkin’s lymphomas: a group of lymphoproliferative disorders that originates in the lymphocytes 
(a type of white blood cells). 
Angiogenesis inhibitors: are agents that inhibit the formation and growth of new blood vessels. 
 
Regarding our compounds, results were interpreted as the possible mechanisms of actions for 
each compound (structural unit) along with Pa value which indicates the estimated probabilities 
for a compound to be active, or pi value which indicates the estimated probabilities for a 
compound to be inactive. Usual interpretation of prediction results is based on the Pa values. If 
Pa value > 0.7 the chance to find the activity in experiment is high, and the compound may occur 
to be close analogue of known pharmaceutical agents. If 0.5 < Pa < 0.7 the chance to find the 
activity in experiment is less, but the compound is not so similar to known pharmaceutical 
agents. If Pa < 0.5 the chance to find the activity in experiment is even more less, but if it will be 
confirmed the compound might occur to be a New Chemical Entity. 
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Result demonstrated that mono substituted derivatives possessing amine substituent at position 2 
of the pyrazine ring (A7 (7), A12 (12), A13 (13), A14 (14), A15 (15), and A16 (16)) exhibited 
different antineoplastic activities. For instance A7 showed good antineoplastic activity especially 
in (non-Hodgkin's lymphoma), while (A12 - A16) showed excellent antineoplastic activity 
mainly against solid tumors with Pa value > 0.7. Moreover, the later derivatives (A12 - A16) 
were able to act as signal transduction pathway inhibitors with very high Pa values that reached 
0.962 for A14. On the other hand, (A13, A15, and A16) were good candidates for preneoplastic 
conditions treatment. 
 
A17 (17), a mono substituted derivative with alkoxy substituent at position 2 of the pyrazine ring 
showed similarity to (A12 - A16) series in manner of predicted activity, but with lower Pa 
values. A structural activity relationship could be derived from this prediction indicating that 
position 2 must be substituted with an amine for better Pa results. 
 
2-amino-3-alkoxy disubstituted derivatives (YAN-1 (18), YAN-2 (19), and YAN-3 (20)) showed 
moderate antineoplastic activity especially in case of (non-Hodgkin's lymphoma). From SAR 
point of view these derivatives are structurally related to A7 (7), they share a common structural 
moiety (1-(5-trifluoromethyl-pyridin-2-yl)-piperazine) which is likely responsible for the 
antineoplastic activity. On the contrary, introducing aliphatic or aromatic alcohol to position 3 of 
the already substituted pyrazine ring resulted in a new cancer non related activity. (YAN-1, 
YAN-2, and YAN-3) showed excellent anti-obesity activity with relatively high Pa values that 
reached 0.925 in case of YAN-3 (20). This again confirms the large spectrum of activity for 
pyrazine derivatives. 
 
Asymmetrical 2,3-diamino substituted derivatives (YAN-4 (21) - YAN-7 (24)) exhibited good 
antineoplastic activity against (non-Hodgkin's lymphoma) with Pa values ≥ 0.6. They also 
showed ability to act as signal transduction pathway inhibitors with different Pa values. This 
difference was structurally related to the presence of certain functional groups at the terminal of 
the derivative, for example having terminal hydrophilic moieties such as hydroxyl or carboxylic 
acid decreased the Pa value of the derivative as signal transduction pathway inhibitor while 
having terminal amine (aliphatic or aromatic) increased the Pa values. 
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Symmetrical di-amino substituted pyrazine derivatives (YAN-8 (25) and YAN-9 (26)) showed 
good antineoplastic activity, particularly (YAN-8 (25) exhibited excellent Pa values. It mainly 
acts as signal transduction pathway inhibitor with Pa value of 0.961, angiogenesis inhibitor with Pa 
value of 0.825, antineoplastic with Pa value of 0.779, and also preneoplastic conditions treatment 
with Pa value of 0.506. These combined mechanisms might result in synergistic effect that could 
increase the possibility of this compound to be active in experiment at lower concentrations. 
 
YAN-10 (27) and YAN-11 (28) are analogous of YAN-5 (22); they were designed by extending 
the carboxylic acid terminal via amide bond. The analogues exhibited the same activities as 
YAN-5 including antineoplastic (non-Hodgkin's lymphoma) and signal transduction pathway 
inhibitory activity. However, the Pa values were different, in case of YAN-10 the Pa values are 
lower than YAN-5 this may refer to the introduction of the methylated carboxylic ester to the 
structure. On the other hand, YAN-11 showed a slightly higher Pa value (as antineoplastic agent) 
than YAN-5. 
 
In order to investigate the importance of derivatization position at the pyrazine ring, the activity 
of 2-amino-5-alkoxy disubstituted derivatives (YAN-13 (30) and YAN-14 (31)) was predicted. 
According to PASS results, the derivatives showed antineoplastic activity against solid tumors 
with very low Pa values of ≤ 0.4. This indicates poor activity in comparison with the 2,3-
disubstituted pyrazine derivatives and hence confirms the importance of the derivatization 
position. 
 
PASS software also predicts the mechanism of action, most of the mono amino derivatives (A13 
- A16) exhibited the same mechanism of action  which is protein kinase inhibitor with different 
Pa values, A14 had the highest Pa value (0.873), followed by A13 with Pa value of (0.706), A15 
and A16 showed lower Pa values of (0.338) and (0.527), respectively. 
 
Accordingly, di-amino substituted pyrazine derivatives (YAN-4 (21) - YAN-8 (25)) possessed 
the same mechanism of action, YAN-8 (25) a symmetrical disubstituted analogue of A14 (posses 
2-aminopyridine in position 2 and 3 of the pyrazine ring) displayed the highest Pa value among 
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the disubstituted derivatives which is (0.954), followed by YAN-7 (24) ,  YAN-4 (21), and 
YAN-6 (23) with Pa values of 0.827, 0.707, and 0.705 respectively. The remaining derivatives 
showed relatively small Pa values ≤0.5. 
 
According to different publications PASS managed to provide robustness of calculated estimated 
data and high accuracy of prediction. The mean accuracy of biological activity prediction with 
PASS is 70±80% both in prediction for independent test and leave-one-out cross validation 
(LOO)
[103, 104]
. Therefore, the results could be used to select the most prospective compounds 
from the set of predicted derivatives for both synthesis and experimental biological screening. 
On top of that, the informative pass predictions could be used to determine the cell lines and 
biological essay that are relevant to the predicted biological activity and mechanism of action for 
each compound. 
 
Some of the predicted derivatives were already synthesized when the PASS prediction was 
carried on; however, other derivatives were synthesized according to their promising activity 
results. 
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3.3.2. Lipinski's rule of five: computational approach to predict drug-likeness of the 
synthesized compounds. Drug-likeness of the synthesized compounds was assisted using 
Chemicalize, A public web resource which gives structure-based predictions. Table 3.3 depicts 
the results. 
 
Table 3.3: drug-likeness prediction results of the synthesized compounds using Lipinski's rule of five. 
 
 
Com. 
# 
Com. 
name 
H-
bond 
donors 
H- bond 
acceptors 
molar 
mass 
g/mol 
log P 
Molar 
refractivity 
Cm
3
/mol 
Atoms 
count 
Pass 
rule of 
five 
1 
2-(3-Chloropyrazin-2-
ylamino)-ethanol 
2 4 173.6 
 
-0.26 
 
44.41 19 yes 
2 
2-[(3-Chloropyrazin-2-
yl)-methyl-amino]-
ethanol 
 
1 4 187.63 0.37 48.64 22 yes 
3 
(3-Chloropyrazin-2-
ylamino)-acetic acid 
 
2 5 187.58 
-0.21 
 
44.20 18 yes 
4 
(3-Chloropyrazin-2-
ylamino)-acetic acid 
methyl ester 
 
1 4 201.61 0.05 48.97 21 yes 
5 
Butyl-(3-chloropyrazin-
2-yl)-amine 
 
1 3 185.66 1.75 51.99 24 yes 
6 
2-(3'-Chloro-2,3,5,6-
tetrahydro-
[1,2']bipyrazinyl-4-yl)-
ethanol 
 
1 5 242.71 0.22 64.69 31 yes 
7 
3‟-Chloro-4-(5-
trifluoromethylpyridin-2-
yl)-3,4,5,6-tetrahydro-
2H [1,2‟] bipyrazinyl 
 
0 5 343.74 3.06 83.03 36 yes 
8 
3'-Chloro-4-(3-
trifluoromethylpyridin-2-
yl)-3,4,5,6-tetrahydro- 
2H-[1,2']bipyrazinyl 
 
0 5 344.74 3.06 83.03 36 yes 
9 
3'-Chloro-4-pyrimidin-2-
yl-3,4,5,6-tetrahydro-
2H-[1,2']bipyrazinyl 
 
0 6 276.73 1.56 75.51 32 yes 
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10 
3'-Chloro-4-pyridin-4-yl-
3,4,5,6-tetrahydro-2H-
[1,2']bipyrazinyl 
 
0 5 275.74 1.59 76.74 33 yes 
11 
1'-(3-Chloropyrazin-2-
yl)-[1,4']bipiperidinyl 
 
0 4 280.8 1.94 79.95 40 yes 
12 
7-(3-Chloropyrazin-2-
yl)-7H-purin-6-amine 
 
1 6 247.65 0.29 75.08 23 yes 
13 
N-(3-Chloropyrazin-2-
yl)-benzene-1,4-diamine 
2 4 220.66 1.57 61.11 24 yes 
14 
(3-Chloropyrazin-2-yl)-
pyridin-2-yl-amine 
 
1 4 206.63 1.77 54.57 21 yes 
15 
 
4-(3-Chloropyrazin-2-
ylamino)-benzoic acid 
 
2 5 249.65 2.01 63.67 25 yes 
16 
4-(3-Chloropyrazin-2-
ylamino)-phenol 
 
2 4 221.64 5.10 58.39 23 yes 
17 
 
N-[4-(3-Chloropyrazin-
2-yloxy)-phenyl]-
acetamide 
 
1 3 263.68 6.08 69.03 28 yes 
18 
 
3'-Ethoxy-4-(5-
trifluoromethylpyridin-2-
yl)-3,4,5,6-tetrahydro- 
2H-[1,2']bipyrazinyl 
 
0 6 353.34 3.03 88.69 43 yes 
19 
 
3'-Isopropoxy-4-(5-
trifluoromethylpyridin-2-
yl)-3,4,5,6-tetrahydro- 
2H-[1,2']bipyrazinyl 
 
0 6 367.37 3.44 93.11 46 yes 
20 
 
3'-Phenoxy-4-(5-
trifluoromethylpyridin-2-
yl)-3,4,5,6-tetrahydro- 
2H-[1,2']bipyrazinyl 
 
0 5 401.39 4.33 103.72 47 yes 
21 
 
N-[4-(5-
Trifluoromethylpyridin-
2-yl)-3,4,5,6-tetrahydro-
2H-[1,2']bipyrazinyl-3'-
yl]-benzene-1,4-diamine 
 
2 7 415.42 3.44 110.67 50 yes 
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22 
4-[4-(5-
Trifluoromethylpyridin-
2-yl)-3,4,5,6-tetrahydro-
2H-[1,2']bipyrazinyl-3'-
ylamino]-benzoic acid 
 
2 8 444.41 3.00 113.22 51 yes 
23 
4-[4-(5-
Trifluoromethylpyridin-
2-yl)-3,4,5,6-tetrahydro-
2H-[1,2']bipyrazinyl-3'-
ylamino]-phenol 
 
2 7 416.40 3.96 107.95 49 yes 
24 
Pyridin-2-yl-[4-(5-
trifluoromethylpyridin-2-
yl)-3,4,5,6-tetrahydro-
2H-[1,2']bipyrazinyl-3'-
yl]-amine 
 
1 7 401.39 3.64 104.12 47 yes 
25 
N,N'-Di-pyridin-2-yl-
pyrazine-2,3-diamine 
 
2 6 264.29 7.47 75.66 32 yes 
26 
2,3-Bis({4-[5-
(trifluoromethyl)pyridin-
2-yl]piperazin-1-
yl})pyrazine 
 
0 8 538.50 4.93 132.59 62 no 
27 
{4-[4-(5-
Trifluoromethylpyridin-
2-yl)-3,4,5,6-tetrahydro-
2H [1,2']bipyrazinyl-3'-
ylamino]-
benzoylamino}-acetic 
acid methyl ester 
 
2 8 515.49 2.97 130.79 61 no 
28 
N-(2-Hydroxy-ethyl)-4-
[4-(5-
trifluoromethylpyridin-2-
yl)-3,4,5,6-tetrahydro-
2H-[1,2']bipyrazinyl-3'-
ylamino]-benzamide 
 
3 8 487.48 2.65 126.23 59 yes 
29 
 
2-(5-Bromo-3-
chloropyrazin-2-
ylamino)-ethanol 
 
2 4 252.5 0.71 52.87 19 yes 
30 
 
2-((3-Chloro-5-
ethoxypyrazin-2-
yl)amino)ethanol 
 
2 5 217.65 0.53 55.94 26 yes 
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The results demonstrate the number of H-bond donors and acceptors, molecular weight, partition 
coefficient, molar refractivity and atoms count for each compound. Rule of 5‟ states that the 
compound should possess less than 5 H-bond donors, 10 H-bond acceptors, molecular weight 
(MWT) smaller than 500 Dalton ( preferred MWT between 180 to 500), calculated octanol-
water partition coefficient (Log P) in −0.4 to +5.6 range, molar refractivity  in 40 to 130 range, 
and finally total number of atoms from 20 to 70. 
 
From the collected data all of the tested compounds successfully met the rule of 5 requirements 
except two of them YAN-9 (26) and YAN-10 (27). This was mainly due to the large molecular 
mass of these compounds which rise from the large implicated substituents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
2-(3-Chloro-5-
isopropoxypyrazin-2-
ylamino)-ethanol 
2 5 231.68 0.95 60.35 29 yes 
32 
N-(3-((6-Chloro-5-((2-
hydroxyethyl)amino)pyr
azin-2-yl)oxy)phenyl) 
acetamide 
 
3 5 322.75 1.07 85.83 37 yes 
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3.3.3. Docking of the synthesized compounds using SwissDock, a protein-small 
molecule docking web service based on EADock DSS. 
3.3.3.1. Docking study using inactive monomeric CDK-2 model 
In order to gain insight into the binding mode of pyrazine derivatives with CDK-2, a series of 16 
compounds were docked with a crystallographic structure of human cyclin dependent kinase-2 
using SwissDock software. First, the crystallographic structure of the target was obtained from 
the Protein Data Bank (PDB), accession code 1-HCL and 
viewed using chimera software (Figure 3.3).  
 
The monomeric CDK2 consists of 298 amino acids and 
folds into a typical bi-lobal structure, consisting of a 
smaller N-terminal lobe (residues 1–85) that contains an 
antiparallel five-strand β-sheet along with a major C-
helix, and a larger C-terminal lobe composed of α-helix 
predominantly. The two terminal domains are connected 
through a single peptide strand (residues 81–83) which 
acts as a hinge linker to ensure the lobes rotation without 
disruption of the kinase secondary structure. It is well 
known that most small agents inhibit CDK2 through 
competition with ATP for the ATP catalytic binding site 
which is located deep at the junction connecting the N and 
C domains, the binding site consists of 136 consecutive 
amino acids (10–145) on the CDK2 including the hinge 
linker region (residues 81–83). Various inhibitors bind to 
the ATP binding pocket and normally occupy the adenine 
ring (subsite) of the ATP.  
 
As the target was determined and prior the docking of our compounds, we need to ensure the 
efficiency of docking and validate the selected target. Therefore, „Aloisine B‟ a synthetic ligand 
with a known affinity to CDK-2 was re-docked with the selected target (PDB1-HCL) using 
SwissDock software (Figure 3.4). 
Figure 3.3: CDK2 (1-HCL.PDB) 
structure in ribbon representation. 
The N-terminal lobe is dominated 
by a five-stranded antiparallel β-
sheet, and the C-terminal lobe is 
predominantly α-helical. Picture was 
taken from chimera software. 
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Docking results demonstrated that Aloisine B occupies the CDK-2 ATP binding site and makes 
hydrogen bonds to the kinase backbone within the hinge sequence that links the two lobes of the 
kinase. These results are in full agreement with the docking results conducted by Yvette Mettey 
and his colleagues in 2002
[72]
, which indicates the efficiency of docking and the validity of  the 
selected target.  
After target determination and validation, our compounds were docked to CDK-2 using 
SwissDock software. Results showed all the possible binding modes of each compound with 
target cavities (blind docking) and their CHARMM energies. The binding modes with the most 
favorable energies were evaluated and clustered, and the most favorable clusters were selected 
and visualized in the UCSF Chimera molecular viewer. Finally, compounds were ranked 
according to their predicted binding energies and full fitness values (Table 3.4). 
 
The docked compounds exhibited distinct binding affinities to the target, compound 25 showed 
the highest full fitness value (-1422.14 kcal/mol) whilst compound 26 showed the lowest full 
fitness value(-1299.70 kcal/mol). In terms of binding mode, pyrazine derivatives occupied the 
CDK-2 ATP binding site and made hydrogen bonds to the kinase backbone within the hinge 
sequence that links the two lobes of the kinase. 
 
Figure 3.4. Docking of CDK2 (1-HCL.PDB) with Aloisine B (A), YAN-8 (25) (B) and A14 
(14) (C). The compounds soak into the CDK-2 ATP binding site. Crystallographic structure 
was taken from chimera software. 
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Table 3.4: docking outcomes of derivatives 14 ,18 ,20 ,21 ,22 ,23 ,24 ,25 ,26 ,27 ,28 ,30 ,31, 32 
and Aloisine B with monomeric CDK-2. Results include estimated binding energies and full 
fitness values as seen in SwissDock and chimera software. 
 
Compound 
Number 
Compound 
Code 
Chimera Model 
Number 
Full Fitness 
(kcal/mol) 
Estimated ΔG 
(kcal/mol) 
Simple fitness 
energy 
14 A14 #1.116 -1405.48 -6.23 24.2 
18 YAN-1 #1.57 -1355.46 -6.87 35.89 
18 YAN-1 #1.73 -1355.39 -6.74 36.9 
19 YAN-2 #1.9 -1353.53 -7.01 38.29 
20 YAN-3 #1.40 -1331.50 -7.29 60.49 
20 YAN-3 #1.231 -1326.08 -7.22 60.04 
21 YAN-4 #1.65 -1348.45 -7.02 62.8 
21 YAN-4 #1.240 -1343.88 -7.05 65.1 
21 YAN-4 #1.157 -1345.51 -7.67 60.30 
22 YAN-5 #1.36 -1342.90 -7.06 64.11 
22  YAN-5 #1.110 -1340.87 -6.91 64.0 
22 YAN-5 #1.183 -1338.29 -7.36 59.87 
23 YAN-6 #1.33 -1347.95 -7.21 59.6 
23 YAN-6 #1.67 -1346.70 -7.24 59.9 
24 YAN-7 #1.29 -1364.35 -7.16 51.92 
24  YAN-7 #1.69 -1362.08 -7.14 53.67 
24 YAN-7 #1.93 -1361.39 -7.39 49.45 
25 YAN-8 #1.11 -1422.14 -6.66 36.9 
25 YAN-8 #1.104 -1417.4 -6.75 36.4 
25 YAN-8 #1.108 -1409.0 -7.0 45.0 
26 YAN-9 #1.130 -1299.70 -7.04 70.31 
26 YAN-9 #1.138 -1299.35 -6.94 78.4 
27 YAN-10 #1.1 -1330.16 -8.13 53.4 
28 YAN-11 #1.41 -1330.74 -8.24 59.1 
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30 YAN-13 #1.32 -1382.33 -6.46 10.4 
31 YAN-14 #1.51 -1377.98 -6.67 14.95 
32 YAN-15 #1.76 -1378.22 -6.77 33.3 
32 YAN-15 #1.222 -1375.15 -7.15 28.2 
Aloisine B   #1.44 -1406.92 -6.64 7.79 
 
Full Fitness: a common docking outcome in SwissDock and Chimera that reflects the fitness of 
the tested compound within a given target. 
Simple fitness energy: the energy of binding that is related to the degree of fitness 
Estimated ΔG: SwissDock outcome representing the estimated difference in free energy of 
binding. 
 
Both the full fitness and energy values indicated that YAN-8 (25) (-1422.14 kcal/mol) has higher 
affinity to the target in comparison to Aloisine B (-1406.92 kcal/mol) and the remaining 
compounds. In terms of structure it is a symmetrical derivative possessing 2-amino pyridine 
substituent at position 2 and 3 of the pyrazine ring, the structure activity relationship that could 
be drawn from that indicated the importance of 2-amino pyridine moiety in binding; moreover, 
this SAR claim was confirmed by A14 (14) which has a mono 2-amino pyridine substituent at 
position 2 of the pyrazine ring and showed high fitness results (-1405.48 kcal/mol). YAN-8 (25) 
showed higher probability of binding because of having 2 hydrogen bond donors and 5 hydrogen 
bond acceptors in its structure whilst A14 (14) has only 1 hydrogen bond donor and 5 hydrogen 
bond acceptors which reduced the chance of binding. Fortunately, these finding are also of high 
agreement to PASS results and scores. 
 
YAN-9 (26) (2,3-bis({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl})pyrazine) showed the 
lowest full fitness value (-1299.70 kcal/mol) among the tested compounds. This is mainly due to 
the large molecular weight and bulkiness of this compound which reduced the chance of fitting 
into the ATP binding site cavity. Moreover, this compound was rejected in term of Lipinski‟s 
rule of five.  
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Conclusion 
Cyclin dependent kinase CDK2 is now recognized as a promising target for structure based 
design of antitumor agents. So far, structural feedback in the rational design of CDK2 inhibitors 
has been derived from complexes of inhibitors with inactive monomeric form of the enzyme.  
 
This research focuses on the synthesis of disubstituted pyrazine derivatives possessing cytotoxic 
and CDK2 inhibitory activity. A set of 2,3-disubstituted pyrazine derivatives were synthesized 
during this study through sequential substitution of the chlorides in 2,3-dichloropyrazine using 
different aliphatic and aromatic amines or alkoxide. The synthesized compounds were purified 
using chromatography techniques, characterized by 
1
H-NMR, FT-IR and ESIMS spectroscopy.  
 
Some of the synthesized compounds were initially assessed for their cytotoxic activity, 
intermediate A-7 (7) and three different disubstituted analogues carrying alcohol substituent at 
position 3 of pyrazine were in vitro screened for their inhibitory activity against two forms of 
acute myeloid leukemia cells (Molm-13). The viability of the cells was determined using WST-1 
assay. A-7 (7) was relatively more potent than its analogues with IC50 of 18 and 39 µM against 
Molm-13 (sh-p53) and Molm-13 (empty vector), respectively. It was noticed that introducing an 
alkoxide substituent at position 3 result in a drop in the activity. However, 1-(5-trifluoromethyl-
pyridin-2-yl)-piperazine pharmacophore showed good antineoplastic activity; hence A-7 (7) was 
chosen as a lead intermidiate. 
 
The biological activity of the synthesized compounds was predicted using PASS software. Initial 
results demonstrated that A13 (13), A14 (14), YAN-7 (24), YAN-8 (25) exhibited potent 
activities as cytotoxic agents and signal transduction pathway inhibitors with relatively high Pa 
values. The previously mentioned compounds also shared the same mechanism of action “protein 
kinase inhibitor” with Pa values larger than 0.8. SAR analysis derived from PASS proved that 
the activity of the synthesized derivative is highly affected by the site and type of the substituent 
on the pyrazine ring. The 2,3-disubstituted derivatives showed better Pa values when compared 
to the corresponding 2,5- disubstituted ones. In addition amine substituents at positions 2 and 3 
of pyrazine ring were preferred over alkoxide substituents in terms of antineoplastic activity.  
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The concept of drug likeness of the mono and di substituted synthesized derivatives was 
investigated by applying the rule of five (RO5). All of the tested compounds successfully met the 
rule of 5 requirements except YAN-9 (26) and YAN-10 (27) which possessed molecular weights 
larger than 500 Dalton. 
In order to gain insight into the binding mode of pyrazine derivatives with CDK-2, a series of 16 
compounds along with ‘Aloisine B‟ -a synthetic ligand with a known affinity to CDK-2- were 
docked with a crystallographic structure of inactive monomeric cyclin dependent kinase-2 using 
SwissDock software. The binding modes with the most favorable energies were evaluated and 
visualized in the UCSF Chimera molecular viewer. Compounds were ranked according to their 
predicted binding energies and full fitness values.  
 
In terms of binding mode, pyrazine derivatives occupied the CDK-2 ATP binding site and made 
hydrogen bonds to the kinase backbone within the hinge sequence that links the two lobes of the 
kinase which means that they belong to the family of ATP-competitive inhibitors. 
 
The docked compounds exhibited distinct binding affinities to the target, YAN-8 (25) showed 
the highest full fitness value (-1422.14 kcal/mol) among the synthesized compounds. Moreover, 
both the full fitness and energy values indicated that YAN-8 (25) has higher affinity to the target 
in comparison to Aloisine B (-1406.92 kcal/mol), a well-known CDK-2 inhibitor. 
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  حضير, وفحص الىشاط السمي لمشتقاث البيرازيه ثىائيت التفرعتصميم, ت
                                                                                                     
  فرعون ربيع لاء محمودآاعذاد: 
  : د. يوسف وجاجرة اشراف
  :ملخص
بيوضتت تبا بير٘زّيتت٘ا   -علتتٔ يتتر٘  بيولاتت ح ر بي ظتتز-ّبئ٘تتا بياتتٖ كشتتو  هشتتات ا بير٘تتزبسٗي كوالتتي بين ٗتت  هتتي بياتت  ٘زبا بي 
ّ هض تبا بيستزا ى.   بيوض تبا بي ْ٘ٗا  هض ت بيرطزٗ ا  ه ربا بيرْح  هض تبا برخالاج  هض تبا بيسكزٕ  بيوسكٌ ا
ب ّ ًج ت بيكلا٘ز هتي بيوشتات ا ًا٘جا يذيي  بظِز بير حلاْى بُاو ه  فٖ هج ح ك ض٘ز برتّٗا بيت ئوا علٔ هشات ا بير٘زبسٗي ُذ
بيْبعت   هِاوت  س يتا لاح بيٌشت ا بيستوٖ  بياٖ كن كظٌ٘نِ  ّف ظِ  فٖ بيْطْح إئ بيوج ح بيستزٗزٕ. ّات ى بحت  بفتزب بير ت 
ّبيذٕ  هي بيووكتي بٗنت سٍ ينت ت هتي بٙي٘ت ا بحت بُ  كلارت٘  -ّبيوض ت يلاك  ز بيذٕ كو ريَ هشات ا بير٘زبسٗي علٔ سنض بيخلاٗ  
 فٖ كظو٘ن بتّٗا ج ٗ   هض ت  يلسزا ى. -ش بيرزّك٘ياٌ٘٘
  
فٖ ُذٍ بي ربيا كن كظو٘ن ّكظٌ٘ع هجوْعا هي هشات ا بير٘زبسٗي بيلاٌ ئ٘ا عرز بريار بح بياسلسلٖ يذربا بيكلْر بيوْجْت  فٖ 
اخ بم كتٌ٘ ا ) سوجوْع ا بخزٓ ا لأهٌ٘ ا ّغ٘زُ . او  كوت كٌت٘ا ُذٍ بيوشات ا س ي3,2-enizaryporohcid( بيوزاب
 .(1H-,RMN31C-TF ,RMN-)ISE(SM dna ,RI )بيرظ  بيكزّه كْغزبفٖ ّكن بيانزف علِ٘  سْبيطا بيا ل٘  بيط٘رٖ 
 
) ّ لا ا هي ًظ ئزُ   ٌ ئ٘ا )7( 7-Aبح تٗا بيارزب ( لوشاتاي  )ytivitca lacigoloib ortiv ni( ٖكن بخار ر بيٌش ا بيرْ٘يْج
ض  ًْع٘ي هخالر٘ي هي خلاٗ  يزا ى بي م بيٌخ عٖ بي  ت. كن  )02( 3-NAY ,)91( 2-NAY ,)81( 1-NAY(( بيارزب
) ا ًت 7). بظِزا بيٌا ئج برّي٘ا يلوشات ا بيور ْطا بى بيوشاتا برح تٗا (1-TSW( ك  ٗ  يلاها بيخلاٗ  س ياخ بم كتٌ٘ا
ّا ى بيازا٘ش بيٌظرٖ بيلاسم يالار٘   ,وساخ ه٘ي بالاز فن ي٘ا هي ًظ ئزُ  بيلاٌ ئ٘ا  فٖ كلار٘  بًاش ر ّكك  ز ًْعٖ بيخلاٗ  بي
 .ه ٗكزّهْرر كر ع  39ّ  18) )rotcev ytpme( 31-mloM dna )35p-hs( 31-mloMبيخلاٗ  بيوذاْر  (
 
) . سٌ٘ت بيٌا ئج SSAPاو  كن كْقع بيٌش ا بيرْ٘يْجٖ يوجوْعا هي هشات ا بير٘زبسٗي بح تٗا ّ ٌ ئ٘ا بيارزب س ياخ بم سزً هج (
بظِزا ق٘ن  )NAY-NAY ,)42( 7-))52(8 ) ّبيوشات ا بيلاٌ ئ٘ا)31( 31A( ,)41( 41Aّي٘ا بى بيوشات ا برح تٗا (بر
) هزكرنا ب رات فن ي٘ا ُذٍ بيوشات ا فٖ بينو  اوض تبا يلاّربم ّهلارط ا يوس ر بش ربا بياٌرَ٘. او  بى seulav aPكْقع (
 .srotibihni esanik nietorp(بينو  ُّٖ كلار٘  سزّك٘ي بيكٌ٘٘ش (بيوشات ا بيوذاْر  ي ست  كش رات فٖ ًرس بي٘ا 
 
ّبير ض برّيٖ يلٌش ا بيرْ٘يْجٖ ب رات بى ًش ا بيوشات ا  SSAP(علاقا بيشك  س يٌش ا بيوساخلظا هي ًا ئج سزً هج (
فن ي٘ا  9ّ 2علٔ بيوْقن٘ي  بيوظٌنا ٗا  ز سوْقع ًّْب بيارزب بيوض ف علٔ حلتا بير٘زبسٗي. ّبظِزا بيوشات ا  ٌ ئ٘ا بيارزب
هي  9ّ2بيارزب هي بيٌْب برهٌٖ٘ علٔ بيوْقن٘ي  ,, س رض فا بئ ذيي5ّ 2بفض  هي بيوشات ا  ٌ ئ٘ا بيارزب علٔ بيوْقن٘ي 
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 ّق  يْحع بى بيوجوْع ا بيا ي٘ا بيرن ي٘ا ض  برّربم.ف٘و  ٗخض  هي بيارزع ا حلتا بير٘زبسٗي ا ى بفض  هي برًْبب برخزٓ
 .ا ًت بفض  هجوْع ا كرزب بهٌ٘٘ا enidiryponima-2 ,enizarepip-)ly-2-nidiryplyhtemoroulfirt-5(-1((
  
, كن رس  هجوْعا  2-KDC(بيوطلْب ( هي بج  بي ظْح علٔ ًظز  كْض٘ ٘ا يطزٗتا بركر ا هشات ا بير٘زبسٗي س رًشٗن
ّكوت هت رًا بيٌا ئج هع بيوزاب )kcoDssiwS(  هشاتا س رًشٗن برح تٕ غ٘ز بيٌش  س ياخ بم سزً هج 18كاكْى هي 
 .ّبيذٕ ٗنارز هلار  هنزّف يٌرس برًشٗن )B enisiolA(
 
) ّق هت سنو  رّبس  ُ٘ رّجٌ٘٘ا هع PTAي٘ا برركر ا بحالت هشات ا بير٘زبسٗي هْقع برركر ا بيخ ص ب (آهي ً ح٘ا 
بيوشات ا  بظِزااو    جشئٖ برًشٗن سرنضِو  بيرنض. بيِ٘ك  بيخ ص س رًشٗن بيْبقع ضوي بياسلس  بيورظلٖ بيذٕ ٗزس
) بعلٔ ق٘وا هْبئوا هع برًشٗن عٌ  هت رًاِ  س يوشات ا )52( 8-NAYق سل٘ا هار ّكا يلاركر ا س يِ ف .ّا ى يلوشاتا (
ٔ يلاركر ا هع )  ٗوالي ق سل٘ا بعل)52( 8-NAYبش را ق٘ن بيوْبئوا ّا قا بيزس  بئ بى بيوزاب (  برخزٓ. علاّ  علٔ ذيي
 .B enisiolAبرًشٗن عٌ  هت رًاَ س يولار  بيونزّف 
 
ى ا  أبظِزا بيٌا ئج  ّق  .ا هي خلاح كطر٘ق بيت ًْى بيخو يٖتّٗلأفٖ بيٌِ ٗا كن بيا تق هي ه ٓ هش سِا بيوشات ا بيو ضز  ي
) ))72( 01-NAY ,( 9-NAY(12()بيوشات ا بيور ْطا ًج ت فٖ هْبفتا هاطلر ا بيت ًْى بيخو يٖ ه  ع ب بيوشاتا٘ي 
  .تبياْى 555ّذيي رهالااِو  بّسبى ذرٗا بارز هي 
 
